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bp base pair
CC corpus callosum
CCT central conduction time
CLN3 juvenile neuronal ceroid lipofuscinosis gene
CLN3 juvenile neuronal ceroid lipofuscinosis, protein encoded by CLN3
CLN5 Finnish variant late infantile neuronal ceroid lipofuscinosis gene
CLN5 Finnish variant late infantile neuronal ceroid lipofuscinosis, protein encoded by CLN5
CLN8 Northern epilepsy syndrome gene
CLN8 Northern epilepsy syndrome, protein encoded by CLN8
CNS central nervous system
CSF cerebrospinal fluid
CT computed tomography
ECD equivalent current dipole
EEG electroencephalography, -gram
EPSP excitatory postsynaptic potential
ER endoplasmic reticulum
ERG electroretinogram
IPSP inhibitory postsynaptic potential
IQ intelligence quotient
ISI interstimulus interval
JNCL juvenile neuronal ceroid lipofuscinosis
kb kilobase pair
LMN left median nerve
LINCL late infantile neuronal ceroid lipofuscinosis
MEG magnetoencephalography
MPRAGE magnetization prepared rapid acquisition gradient echo
MRI magnetic resonance imaging
MRS magnetic resonance spectroscopy
NCL neuronal ceroid lipofuscinosis
NES Northern epilepsy syndrome
PET positron emission tomography
PME progressive myoclonus epilepsy
PPC posterior parietal cortex
PSP postsynaptic potential
RMN right median nerve
SD standard deviation
SEF somatosensory evoked magnetic field
SEP somatosensory evoked potential
SI primary somatosensory cortex
SII secondary somatosensory cortex
SIIc contralateral SII
SIIi ipsilateral SII
SPECT single photon emission computed tomography
SQUID superconducting quantum interference device
TE echo time
TR repetition time
ULD Unverricht–Lundborg type of PME
VEP visual evoked potential
VPL ventral posterolateral nucleus of the thalamus
VPM ventral posteromedial nucleus of the thalamus
vLINCLFin Finnish variant late infantile NCL
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81. ABSTRACT
Background: Neuronal ceroid lipofuscinoses (NCLs) are autosomally recessively inherited
progressive encephalopathies that are known to occur world-wide. To date, thirteen different
forms of NCL have been identified, all of which are characterized by the accumulation of ceroid
and lipofuscin like material. The clinical symptoms are caused by neuronal dysfunction and
death, the timing and pattern of which vary according to the different forms of the disease. In
recordings of somatosensory evoked potentials (SEPs), the infantile form of NCL has been shown
to lead to extinction of the responses, whereas the late infantile forms are associated with so-
called giant (high amplitude) SEPs. In juvenile forms, the findings have varied from attenuated to
enhanced SEPs. Some of this discrepancy may be due to the fact that the progression of the NCL
disease causes physical changes (e.g., the amount of cerebrospinal fluid increases, the skull
becomes thicker), which will distort the signal between the active brain source and the measuring
device when using electroencephalographic (EEG) techniques. Thus, magnetoencephalography
(MEG), which records synchronous neuronal activity in the way as EEG, but is insensitive to the
different electrical conductivities, would better reflect the underlying neuronal activation in NCL
diseases. Furthermore, the neuronal activity originating from the different cortical areas
participating in somatosensory processing can be modelled using MEG.
Purpose and methods: We used MEG to examine in detail somatosensory cortical responses to
median nerve stimulation in three genetically different forms of NCL in order to study the effects
of the NCL gene defects on the functioning of neurons of the somatosensory pathway. The
patients included 24 with juvenile NCL (JNCL), 4 with Northern epilepsy syndrome (NES) and 5
with Finnish variant late infantile NCL (vLINCLFin). The somatosensory evoked magnetic fields
(SEFs) of the patients were compared with those of healthy controls in the same age range.
Altogether 27 healthy subjects, 17 of whom were under 19 years of age, were measured. In
patients with JNCL and vLINCLFin, the SEFs, structural brain changes evaluated using magnetic
resonance imaging (MRI), and some clinical findings were further investigated for phenotypic
differences. In addition, the brain MRIs of NES patients were visually and quantitatively
analyzed.
Results: In the normal controls, the responses from the primary somatosensory cortex (SI) were
of similar morphology in all subjects throughout the whole age range, and consisted of
identifiable N20m, P35m and P60m deflections. The early N20m responses were significantly
stronger in older subjects than in younger subjects. A similar trend was seen also for the P35m
strength. The height and age of the subject had the greatest influence on the N20m latency.
Activity from contra- and ipsilateral secondary somatosensory cortex (SII) was seen in 83% and
72% of the subjects, respectively.
In JNCL, the SEFs from SI were normal in patients between 6–11 years of age. After that the
responses became stronger, 68% of the first cortical N20m deflections and 39% of the following
P35m deflections being abnormally strong. The different mutations in the CLN3 underlying
classic or delayed classic forms of the disease did not affect the SEF strengths differently.
However, the phenotype of the two patients who were compound heterozygous for the major
1.02-kb deletion and a missense mutation, was atypically protracted with milder than expected
MRI findings and normal or only slightly enlarged SEFs. A slight prolongation of the N20m
latency was seen among all the different phenotypes.
9In the patients with NES (gene symbol CLN8; age range 26–43 years), the SEFs were mainly
within normal limits. Their MRIs showed only mild cerebral atrophy combined with more
prominent cerebellar atrophy. In addition, no pathologically altered signal intensities of the brain
structures were found, thus distinguishing NES from JNCL and vLINCLFin.
The most pathological findings were observed in patients with vLINCLFin, which is caused by
mutations in the CLN5 gene. All five patients studied, between the ages of 8–16 years, had
abnormally strong SI responses with a delayed N20m latency. The strength of the responses was
clearly greater than in patients with JNCL. Furthermore, the morphology of the SI deflections
differed from that of the normal controls: the extremely strong N20m and P35m were followed by
N45m, a deflection that was not seen in the controls. In addition, the normally occurring P60m
was not seen in patients. The increased excitability of the somatosensory system was also seen as
an enlargement of the SII responses in four patients. The patients with the mutations predicted to
result in the most severely truncated proteins showed the strongest responses, indicating that there
may be a subtle link between genotype and neurophysiologic phenotype.
Conclusion: The median nerve SEFs, reported for the first time in a relatively large number of
children and adolescents, showed that the SEFs in healthy children over 6 years are
morphologically similar to those in adults. However, new information about the development of
SEFs, e.g., that both the N20m and P35m become stronger with age, was demonstrated. Thus, the
need for age-matched control groups is emphasized when children and adolescents are studied.
The present studies demonstrate that the use of MEG is feasible when studying children with a
severe degenerative brain disease like NCL. The enlargement of the early SI deflections in JNCL
with the progression of the disease and the presence of enlarged SII deflections in vLINCLFin
were demonstrated for the first time, indicating that MEG may uncover new information about
defective neuronal function in these diseases. The pathogenesis of JNCL and vLINCLFin were
shown to lead to enlargement of SEFs, suggesting that the diseases disturb the balance between
inhibition and excitation of the somatosensory network. In contrast, although inclusions
characteristic for NCL diseases are seen in the neurons of patients with NES at autopsy, the well
preserved cerebrum and normal SEFs suggest that the underlying CLN8 gene defect is relatively
well tolerated by the neurons of the somatosensory network.
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2. INTRODUCTION
Neuronal ceroid lipofuscinoses (NCLs) are autosomally recessively inherited progressive
encephalopathies, known to occur world-wide. They are characterized by the accumulation of
ceroid and lipofuscin like material in storage cytosomes that leads to neuronal dysfunction and
death (Zeman et al., 1970; Santavuori et al., 2000). Clinically, NCL diseases can be classified
into 13 different forms that are caused by defects in at least 8 different genes, located on different
chromosomes (Mole, 1999). Three of the proteins involved in NCL pathogenesis are known to be
associated with lysosomal function, but the reason for neuronal damage is not known. Although
the disease affects virtually all neurons in the central nervous system, the pattern and timing of
the neuronal dysfunction and death vary between different neuronal populations and between the
forms of NCL. Macroscopically, a progressive brain atrophy associated with pathological signal
intensities of the brain is detected using magnetic resonance imaging (MRI; Autti et al., 1997b).
The functioning of the affected neurons is more difficult to assess; however, one method of
objectively evaluating the integrity of the sensory system is to record cortical evoked responses.
The infantile form of NCL that leads to the death of virtually all cerebral neurons is associated
with the extinction of evoked potentials by the age of 4 years (Vanhanen et al., 1997). However,
the progressive death of neurons in the late infantile NCL forms leads to increased amplitudes of
visual and somatosensory evoked potentials (VEPs and SEPs, respectively; Pampiglione and
Harden, 1977; Santavuori et al., 1991). In juvenile NCL, VEPs are known to become attenuated
(Harden and Pampiglione, 1982; Santavuori et al., 1988), but SEPs have been reported to be of
decreased (Goebel, 1995) or increased amplitude (Schmitt et al., 1994), or even normal (Cracco
et al., 1980; Harden and Pampiglione, 1982). This discrepancy in the findings can be partly due to
the fact the studies have been performed at a time when genetic confirmation of the diagnosis was
not possible, and thus the patient material may have been heterogeneous. Furthermore, the
patients have been studied in different stages of their disease. Since the electroencephalographic
(EEG) techniques are influenced by the electrical conductivities of the media between the brain
source and the measurement device, the progression of NCL that causes brain matter to decrease,
the amount of cerebrospinal fluid to increase and the skull to thicken, can affect the electric
potentials measured with EEG and lead to inconsistent results.
The magnetic field caused by an activation within the brain is not altered by the conductivity of
the intervening media, and can be measured with magnetoencephalography (MEG). With MEG,
neuronal activity that generates tangential currents can in many cases be modelled with equivalent
current dipoles (ECDs) and localized in the corresponding brain areas (Hämäläinen et al., 1993).
Thus, measuring somatosensory evoked magnetic fields (SEFs; Hari and Forss, 1999) has the
advantage that the origin of the responses and the strength of the underlying activity can be
accurately assessed.
The aim of this Thesis was to evaluate the integrity of the somatosensory system in three of the
NCL forms (juvenile NCL, the Finnish variant late infantile NCL, and Northern epilepsy
syndrome) by recording somatosensory evoked responses using MEG.
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3. REVIEW OF THE LITERATURE
3.1. NEURONAL CEROID LIPOFUSCINOSES (NCLS)
3.1.1. Overview
The first report of patients most likely affected with neuronal ceroid lipofuscinoses dates back to
the beginning of the 19th century (Stengel, 1826), but it was only 1969 when Zeman and Dyken
named the disease group as NCL, thus differentiating it from the other “amaurotic familial
idiocies” (Zeman and Dyken, 1969). Childhood-onset NCL diseases, inherited in autosomal
recessive fashion, form the largest group of inherited progressive encephalopathies world-wide.
The common denominator in these diseases is the accumulation of autofluorescent, ceroid and
lipofuscin like material in storage cytosomes, leading to neuronal death (Zeman et al., 1970;
Rapola, 1993). Clinically, NCLs have been divided into four major types: infantile, late infantile,
juvenile and adult forms (Goebel, 1995; Santavuori et al., 2000). At present, altogether eight
different gene loci are known to underlie the NCL forms (Table 1); and it has become apparent
that a clinically defined patient group can include individual patients with defects in different
NCL genes (Das et al., 1998). Furthermore, the individual NCL phenotypes are influenced by the
modifying genes and environmental factors (Järvelä et al., 1997; Munroe et al., 1997).
Table 1. Classification of NCL diseases
Gene
locus
Chromosome
location
Mutations* Gene product Clinical type
CLN1 1p32 37 lysosomal palmitoyl protein
thioesterase
infantile, late infantile,
juvenile
CLN2 11p15 41 lysosomal pepstatin-insensitive
peptidase
late infantile
CLN3 16p12 31 (lysosomal) transmembrane CLN3
protein
juvenile
CLN4 not known not known adult
CLN5 13q22 4 transmembrane CLN5 protein Finnish variant late infantile
CLN6 15q21–23 not known early juvenile/
variant late infantile
CLN7 not known not known early juvenile/
variant late infantile
CLN8 8p23 1 endoplasmic reticulum/Golgi
protein
Northern epilepsy
* described in NCL mutation home page (http://www.ucl.ac.uk/ncl, accessed on 10/6/2001). See text for references.
The clinical manifestation of NCL is caused by neuronal dysfunction. The characteristic
symptoms are epilepsy, mental retardation, motor dysfunction and in most cases blindness. The
pattern, timing and severity of these symptoms differ between the different childhood NCL forms
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(Santavuori, 1988; Santavuori et al., 2000). A congenital form evident at birth is extremely rare.
Infantile form (also known as Santavuori–Haltia disease), caused by mutations in CLN1,
progresses rapidly leading to total loss of active motor and cognitive skills by the age of 3 years,
which is also the time when EEG usually becomes isoelectric. The late infantile phenotypes can
be caused by mutations in five different NCL genes (Table 1). The classic late infantile NCL
(Jansky–Bielschowsky disease) manifests itself with seizures and progressive dementia between
the ages of 2 and 4 years with additional signs of myoclonia and ataxia, and visual failure that
becomes apparent later. The juvenile form (Batten or Spielmeyer–Vogt–Sjögren disease), starts
with visual deterioration at early school age (6–10 years), and is followed by mental and motor
deterioration, progressing slowly until death at mean between the ages of 20 and 30 years. The
newest member of NCL is Northern epilepsy syndrome that manifests with epilepsy usually
before the age of ten, and leads to mental and motor deterioration, but is not associated with
blindness. The adult form (Kufs disease; e.g., Berkovic et al., 1988) is a variable condition
appearing around the age of 30 years, and in addition to the recessively inherited forms,
dominantly inherited forms are also known. For example, the overall incidence of NCL has been
estimated to be 1.28 per 100 000 live births in West Germany (Claussen et al., 1992). In some
areas, the incidence of NCL is higher; for example in Finland, 7.7 and 4.8 per 100 000 live births
for infantile and juvenile NCLs, respectively (Santavuori, 1988).
The molecular basis underlying NCLs is still unknown, although recent findings implicate
impaired degradation in lysosomes. Two soluble lysosomal enzymes, palmitoyl protein
thioesterase (PPT), which removes fatty acids from acetylated proteins (Camp and Hofman, 1993;
Lu et al., 1996), and tripeptidyl peptidase I (TPP1), which cleaves three amino acids from
proteins undergoing degradation within lysosomes (Vines and Warburton, 1999), are known to be
defective in CLN1 and CLN2 forms of NCL, respectively. In addition, the CLN3 protein has also
been suggested to lie within the lysosomal membrane (Järvelä et al., 1999). Ultrastructurally, the
accumulated autofluorescent lipopigments consist of granular, curvilinear, rectilinear and
fingerprint patterns, which can be visualized using electron microscopy (Elleder et al., 1999). The
main component of the storage material in most NCL forms is subunit c of mitochodrial
adenosine triphosphate (ATP) synthase (Hall et al., 1991; Palmer et al., 1992), but in the infantile
type the accumulated material consists mainly of saposins A and D (Tyynelä et al., 1993).
There is no curative or preventive treatment available today. The symptomatic treatment includes
medication for epilepsy, muscle relaxants, antiparkinson medication, sedative drugs, analgesics,
antidepressants and antipsychotics (e.g., Åberg et al., 2000). In addition, some patients with
JNCL are thought to benefit from antioxidant therapy (Santavuori et al., 1988). In many patients
also psychotrophic medication is needed.
This Thesis deals with three of the NCL forms, namely juvenile, Northern epilepsy syndrome and
the Finnish variant late infantile. These three forms are described in detail in the following.
3.1.2. Juvenile NCL (JNCL, CLN3)
General
The first patients, retrospectively believed to be affected by JNCL, were four siblings from
Norway (Stengel, 1826). Over the years several eponyms, including late onset Batten disease and
Spielmeyer–Sjögren disease, have been associated with JNCL. Although the basic characteristics
of JNCL have remained the same over the years, patients born with the disease today have a
better prognosis than did the patients at the beginning of the 20th century (Sjögren, 1931).
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Although the disease is still fatal, the quality of life for patients has improved significantly, since
the disease can be diagnosed early, patients receive rehabilitation and proper symptomatic
medication. In Finland, the incidence of JNCL has remained similar over the years, and is 1 per
21 000 live births with a prevalence of 12 per million inhabitants (Uvebrant and Hagberg, 1997).
Clinical Picture
During the first few years of their lives the patients are normal, healthy children. The first sign of
the disease, a progressive loss of vision, is noticed usually between the ages of 4 and 8 years.
Most children with JNCL attend normal school for the early grades, but as their sight worsens
(most patients become blind between the ages of 6 and 13), they switch to special schools. Mental
retardation usually becomes evident between the ages of 8 and 12 (Santavuori et al., 2000). The
first epileptic seizure occurs in most patients soon after the age of ten (Hofman et al., 1999;
Åberg et al., 2000). The timing of a parkinsonian type of extrapyramidal dysfunction, manifesting
itself first as slight truncal ataxia, varies markedly between patients (Järvelä et al., 1997). Rigidity
is slight at beginning but worsens with time, and there is difficulty in initiating movement. Most
patients become non-ambulant between the ages of 15–28 years (Järvelä et al., 1997). Dysarthria
develops to anarthria in the majority at the late stage of the disease. A number of the patients have
myoclonic jerks during the late stage of their disease, however these myoclonic features can be
confused with partial epileptic seizures. Many patients have behavioural problems, and psychoses
with hallucinations are not uncommon (Santavuori et al., 1993). The most commonly used
antiepileptic drugs to control the seizures are lamotrigine and sodium valproate in monotherapy,
combined later with benzodiazepine (Åberg et al., 2000). Parkinsonian symptoms are medicated
with L-dopa in combination with bromocriptin. Some patients benefit from baclophen and
tizanidine. In addition, most patients with JNCL are on antioxidant therapy (Santavuori et al.,
1988).
Within the JNCL disease, three disease courses progressing at different rates can be identified. In
classic JNCL, significant mental retardation (IQ level reduced by more than 10 points from the
time of diagnosis) takes place before the age of 10 years, parkinsonian signs emerge before the
age of 15, and death occurs usually around the age of 20 and not later than 25 years (Sjögren,
1931; Järvelä et al., 1997). The delayed classic JNCL progresses less rapidly: significant mental
retardation is seen soon after 10 years, parkinsonian signs after 15, and death usually after 25
years (Järvelä et al., 1997). The third form, called the protracted JNCL, starts typically at an early
age with progressive visual loss, but the mental and motor symptoms manifest themselves later,
usually in the third or fourth decade of life (Goebel et al., 1976a; Libert et al., 1982; Wisniewski
et al., 1998).
Genetics
The gene for juvenile neuronal ceroid lipofuscinosis, CLN3, was isolated on chromosome
16p11.2–12.1 (The International Batten Disease Consortium, 1995). It is composed of at least 15
exons and 14 introns (Mitchison et al., 1997a, 1997b), and encodes a protein consisting of 438
amino acids. The major mutation, a 1.02-kb deletion, present in 81% of the disease chromosomes
(The International Batten Disease Consortium, 1995), is still further enriched in the isolated
population of Finland (Järvelä et al., 1996). This major deletion removes exons 7 and 8 from the
transcript, and is predicted to give rise to a truncated protein consisting of the first normal 153
amino acids followed by 28 novel residues. At present day, in addition to the major deletion,
thirty different mutations have been described in CLN3 (http://www.ucl.ac.uk/ncl, accessed on
10/6/2001). These include 7 deletions, 4 insertions, 1 intron change as well as 4 splice site, 7
missense and 7 nonsense mutations. Most of these mutations cause frameshift and/or truncation
of the protein. However, the 7 missense mutations change only one amino acid residue and may
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thus result in only slight modification of the CLN3 protein. However, it must be noted that in
many genes, like for example in CLN1, change of only one amino acid can have detrimental
effects (Hellsten et al., 1996).
The function of the CLN3 protein, also called battenin, remains unknown. It has been shown to
traffic through the endoplasmic reticulum (ER) and the Golgi apparatus (Haskell et al., 1999),
and is most likely located on lysosomal membrane (Järvelä et al., 1998). Recently, a yeast model
has implicated that CLN3 protein plays a role in the regulation of lysosomal pH (Pearce et al.,
1999).
Genotype-Phenotype Correlation
The patients homozygous for the major 1.02-kb deletion have either the classic or delayed classic
disease course (Järvelä et al., 1997). The intrafamiliar variability may be large, and it seems that
environmental factors as well as modifying genes, play an important role in the individual
phenotype of a JNCL patient (Järvelä et al., 1997; Munroe et al., 1997). Because of the variability
of the disease course, even among the patients homozygous for the major 1.02-kb deletion,
differences caused by different genotypes, e.g., in patients compound heterozygous with the 1.02-
kb deletion and another mutation, are difficult to demonstrate. However, some differences may
exist. It seems that the patients homozygous for the major 1.02-kb deletion may have more
pathologically altered sleep (Kirveskari et al., 2000) and brain MRI findings (Järvelä et al., 1997).
In addition, an extremely protracted course of the disease, with predominantly only ocular
symptoms during the first two to three decades, has never been reported in patients homozygous
for the 1.02-kb deletion (Järvelä et al., 1997; Munroe et al., 1997; Wisniewski et al., 1998).
Neuropathology
At autopsy, brain weights are reduced to 800–1000 g; the macroscopic appearance of the brain is
slightly smaller than normal due to the diffuse cortical atrophy. The skull bones are thickened.
Histologically, there is a variable loss of neurons affecting mainly layers II and V (Braak and
Goebel, 1978, 1979). In particular, the small stellate neurons in layer II have disappeared at the
time of autopsy. Nerve cells are lost in the corpus striatum and the amygdaloid nucleus; also
especially the medial parts of the thalamus are affected (Autti et al., 1997a). Atrophy of the
cerebellum shows considerable variation: in some patients there is no cerebellar atrophy, whereas
in others the cerebellar atrophy may be more advanced than the cerebral atrophy (Zeman et al.,
1970; Hofman et al., 1999). Histologically, a reduction of the dendritic trees of Purkinje cells
may be conspicuous despite relative preservation of the cells themselves. The granular layer is
severely depleted.
Neuroimaging
Brain computed tomography (CT) is usually normal until the age of about 9 to 10 years
(Lagenstein et al., 1981; Raininko et al., 1990). After that the cerebral atrophy usually precedes
the cerebellar atrophy (Nardocci et al., 1995). In MRI studies of 30 patients, Autti et al. (1996)
found cerebral atrophy in all patients over 15 years of age, whereas cerebellar atrophy was seen in
patients over 19. Also the brain stem became atrophic with the progression of the disease. The
signal intensity ratios of the deep grey and white matter decreased with the progression of the
disease, and the pathological finding of dark thalami compared with the basal ganglia on T2-
weighted images could be seen after the age of 10 years. However, these pathological deep grey
to white matter ratios were seen only in JNCL patients homozygous for the 1.02-kb mutation
(Järvelä et al., 1997). Increased signal intensity of the white matter, especially beside the lateral
ventricles is another typical, but unspecific, finding and has been demonstrated to be correlated
with neuronal loss and gliosis (Autti et al., 1997a).
15
In agreement with structural MRIs, a proton magnetic resonance spectroscopy (MRS) study of 3
JNCL patients under 12 years of age showed normal metabolic profiles of N-acetyl aspartate
(NAA), creatine and phosphocreatine (Cr), choline-containing compounds (Cho), myo-inositol
(Ins) and lactate (Lac; Brockmann et al., 1996). After 4 years of follow-up, one patient showed
reductions of NAA, Ins and Cr of grey matter relative to the first examination, thus indicating
neuronal death.
Hypoperfusion of several brain areas, with no clear correlation with age, was typically seen in all
JNCL patients (aged 8 to 28 years) studied using single photon emission computed tomography
(SPECT) after an injection of technetium-99m labelled hexamethylpropyleneamine oxime
(99mTc-HM-PAO; Launes et al., 1996). However, an age-related progression of distinctively
decreased metabolic activity was demonstrated in positron emission tomography (PET) with
fluorodeoxyglugose: metabolic activity decreased first in the calcarine area and then spread to
involve the entire cortex, sparing only the basal ganglia and brainstem (Philippart et al., 1994).
Electrophysiological Findings
EEG findings in JNCL are usually normal until the age of 9 years, after which progressive
background abnormalities with spike-and-wave paroxysms appear (Westmoreland et al., 1979;
Raininko et al., 1990; Larsen et al., 2001). The focal paroxysms become generalized in patients
over the age of 12 years. No nocturnal epileptic seizures are observed during polysomnographic
(PSG) recordings, occasional paroxysmal activity is seen in light sleep and REM (rapid eye
movement) sleep (Kirveskari et al., 2000).
The electroretinogram (ERG) is low or even missing at the time of diagnosis, followed later by
the disappearance of the flash-VEP around the age of 13–16 years (Pampiglione and Harden,
1977; Santavuori et al., 1988). SEPs have been described as normal (Cracco et al., 1980; Harden
and Pampiglione, 1982) or decreased (Goebel, 1995), however, one patient with enhanced SEPs
and bilaterally prolonged central conduction time (CCT) has been reported (Schmitt et al., 1994).
Motor and sensory nerve conduction velocities have been reported to be normal (Santavuori et
al., 1985) or slightly slow in patients of all ages (Blatt Lyon, 1975).
3.1.3. Northern Epilepsy Syndrome (NES, CLN8)
General
Northern Epilepsy Syndrome, NES, an inherited childhood epilepsy with mental retardation
(EPMR), was recently characterized as belonging to the NCL family. This disease has been so far
described in 26 patients from the Kainuu region in Finland (Hirvasniemi et al., 1994, 1995).
Clinical Picture
Clinically, NES can be divided into three successive stages. The first stage begins with epilepsy at
the mean age of 6.7 years (range 5–10 years); the seizures are typically short generalized tonic-
clonic attacks, but complex partial seizures also occur (Hirvasniemi et al., 1995). At first the
seizures occur once every month or two; however, despite antiepileptic medication the seizure
frequency increases until puberty when one or two attacks per week are common. The
antiepileptic drug of choice to control the seizures is clonazepam. Mental deterioration becomes
evident two to five years after the onset of epilepsy, and seems to be most rapid at the time of the
most frequent epileptic attacks. During the second stage in young adulthood, the frequency of
seizures diminishes and the mental decline is slower, but the first signs of clumsiness in fine
motor tasks appear. Nearly half of the patients have behavioural problems. The third stage of
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permanent disability includes few seizures and continuing retardation, evident clumsiness,
balance difficulties and often decreased visual acuity (Hirvasniemi et al., 1994). The life
expectancy of NES patients is not at this time known, but it may be slightly shorter than normal
(Herva et al., 2000).
Genetics
The NES gene, CLN8, was localized to chromosome 8 (Tahvanainen et al., 1994), and encodes a
putative transmembrane protein of 286 amino acids (Ranta et al., 1999). So far, one disease
causing mutation and two polymorphisms in CLN8 have been found. Recent evidence suggests
that the CLN8 protein is a resident of the endoplasmic reticulum (ER) and recycles between the
ER and Golgi (Lonka et al., 2000).
Genotype-Phenotype Correlation
Since all known Finnish NES patients are homozygous for a missense mutation (70C→G, R24G)
genotype-phenotype correlation cannot be assessed (Ranta et al., 1999).
Neuropathology
Compared with other childhood-onset NCLs the overall degree of intraneuronal storage, neuronal
loss, and secondary astrocytic and microglial reaction are much less pronounced in NES.
Although granular cytoplasmic storage material is present in virtually all neurons, the amount of
storage material varies greatly within different neuron populations. Most prominent storage
occurs in the hippocampus, while slight to moderate storage without evident neuronal loss occurs
in the basal ganglia and thalamus. On the cerebral cortex, the pyramidal cells of the deeper parts
of lamina III are severely ballooned, while conspicuous axonal enlargements (spindles or
meganeurites filled with storage cytosomes) are a frequent feature in the less ballooned nerve
cells of the more superficial parts of this layer. (Haltia et al., 1999) In the cerebellum, neuronal
death and the accumulation of ceroid and lipofuscin like material are minimal: with a few
exceptions the Purkinje cells are intact and the granular cells show only very modest storage
material accumulation. However, the dentate, pontine and inferior olivary neurons show moderate
storage (Herva et al., 2000).
Neuroimaging
Cerebral atrophy was seen in a CT study in 15 out of 16 patients over 19 years of age. In the
patients with cerebral atrophy, epilepsy had lasted more than 12 years (Hirvasniemi and Karumo,
1994). Cerebellar and brainstem atrophy was already evident in the youngest patient at the age of
10 years. However, a MRI of a 10-year-old patient was normal, a 16-year-old patient had slight
cerebellar atrophy and 24-year-old had slight cerebral and moderate brainstem and cerebellar
atrophy.
Electrophysiology
EEG shows slowing of the background activity, abundant diffuse or intermittent delta and theta
activity and scanty epileptiform activity with varying localization and form (Lang et al., 1997).
VEPs were abnormal in 44% of the patients and brainstem auditory evoked potentials (BAEPs) in
35%. There are no published reports of SEPs in NES.
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3.1.4. Finnish Variant Late Infantile NCL (vLINCLFin, CLN5)
General
Four different forms of late infantile NCL, known also as the Jansky–Bielschowsky disease, are
known today (Table 1). The classic LINCL (CLN2) and the so-called CLN6 variant late
infantile/early juvenile patients exist in several countries, whereas all the patients reported to have
the CLN7 variant have originated from Turkey (Williams et al., 1999). Some patients have a
mutation/mutations in CLN2 that results in a disease that manifests abnormally late in childhood
(Sleat et al., 1999). In addition, clinical LINCL phenotype can be caused by mutations in the
CLN1 gene (Das et al., 1998). The CLN5 patients come almost exclusively from Finland, and
thus the disease is denoted as the Finnish variant LINCL, vLINCLFin. The prevalence of
vLINCLFin in Finland is 2.6 per million inhabitants (Uvebrant and Hagberg, 1997).
Clinical Picture
The first signs of vLINCLFin are slight clumsiness and muscular hypotonia between 4.5 and 6
years of age. Before that, the children may have had some concentration, visuomotor or learning
problems. Visual failure is noticed between 5 and 8 years. Epileptic seizures, which appear
around the age of 7 to 10 years, are usually generalized, but partial and complex partial seizures
also occur. Broad-based walk, ataxia and myoclonus appear after 7 to 8 (10) years of age. Drug
therapy usually includes at first valproate, which may later be combined with lamotrigine and
clonazepam. In addition, baclophen and tizanidine are required for preventing myoclonic jerks,
dystonia and the formation of contractures. Patients become non-ambulant usually at the age of
9–11 years, although some patients are able to walk supported until the age of 13. Death occurs
usually between the ages of 14 and 32. (Santavuori et al., 1982, 1991)
Genetics
vLINCLFin is caused by mutations in the CLN5 gene, which is located on chromosome 13 and is
suspected of encoding a membrane protein the cellular location of which is as yet unknown
(Savukoski et al., 1998). To date, four different mutations in the CLN5 are known. The Fin major
mutation, a 2-bp deletion in exon 4, is detected in 94% of the Finnish disease chromosomes. It is
predicted to give rise to a truncated polypeptide of 391 amino acids instead of the expected 407.
A nonsense mutation in exon 1 (called Fin minor) causes a truncated polypeptide of only 74
amino acids. One missense mutation has been described in a Dutch patient, and it is predicted to
change one residue in exon 4 from aspartic acid (Asp) to asparagine (Asn). The last known
mutation of CLN5, called Swedish mutation, is a 1-bp insertion in exon 3, expected to cause a
truncated protein of 224 of the original amino acids followed by 29 novel amino acids (Holmberg
et al., 2000)
Genotype-Phenotype Correlation
Although three of the mutations are predicted to cause a truncated protein and one only to change
one residue from aspartic acid (Asp) to asparagine (Asn), all the mutations seem to result in a
similar phenotype, when eight patients were studied clinically and with MRI (Holmberg et al.,
2000). Thus it seems that all the known CLN5 mutations result in functional null allele. Thus the
location of the missense mutation that changes one residue must be in a functionally important
part of the CLN5 protein.
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Neuropathology
Autopsy findings have revealed an advanced loss of neurons in the cerebral cortex, often in
laminar pattern particularly involving layers III and V (Tyynelä et al., 1997; Santavuori et al.,
1999). The remaining cortical neurons have numerous fusiform axonal enlargements (spindles or
meganeurites), particularly affected are the neurons in the superficial part of layer III. Also the
cerebellum is uniformly and extremely atrophic with almost complete destruction of the granule
cells and Purkinje cells, while the few preserved Purkinje cells and their dilated dendrites are
loaded with storage granules. The thalamus shows severe loss of neurons but otherwise the
subcortical structures have only mild-to-moderate neuronal loss, but moderate-to-pronounced
intraneuronal ballooning. The cerebral white matter shows moderate to severe loss of myelin and
gliosis, particularly advanced in the periventricular white matter and in the cerebellar folia (Autti
et al., 1997a).
Neuroimaging
Cerebellar atrophy is more prominent than cerebral atrophy during the early stages of the disease:
in most patients cerebral atrophy can only be seen after the age of 8 years, whereas cerebellar
atrophy is already evident on the diagnostic MRI scan, taken usually around the age of 6
(Holmberg et al., 2000). Also the brain stem is atrophic (Autti et al., 1992). Hyperintense white
matter zones around the lateral ventricles, decreased signal intensity of the thalamus compared
with putamen and nucleus caudatus and a constant hyperintensity of the posterior limb of the
capsula interna on T2-weighted images are evident from the age of 6 years. SPECT in vLINCLFin
patients has revealed moderate or severe cerebellar hypoperfusion, and also focal hypoperfusion
of one or more of the supratentorial regions (Autti et al., 1992).
Electrophysiology
In EEG, progressive background abnormalities and paroxysmal activity, including spikes and
spike and wave paroxysms, are typically noticed between 4–7 years of age (Santavuori et al.,
1982). The characteristic electrophysiological findings of posterior spikes in EEG during a low-
frequency photic stimulation, detected from the age of 7–10.5 years, and giant visual (around 7–
9.5 years) and somatosensory evoked potentials (around 7.5–9.5 years), are of diagnostic
significance (Santavuori et al., 1999). ERG disappears around the age of 6–9 years.
3.2. ANATOMY OF THE SOMATOSENSORY SYSTEM
3.2.1. Ascending Somatosensory Pathways
The peripheral somatosensory receptors receive tactile, temperature, pain and proprioceptive
stimulation. In the spinal cord, this information is carried towards the somatosensory cortex
mainly by dorsal column-lemniscal and anterolateral systems. The sensations of touch, vibration,
position and pressure are mediated by large, myelinated fibers in the dorsal columns up to the
medulla, where they synapse at the dorsal column nuclei (the cuneate nucleus for upper
extremities and gracile nucleus for lower limb and other body parts). The second-order neurons
decussate to the opposite side, and carry the signal to the thalamus via the medial lemniscus. The
thin fibers of the anterolateral system carry pain, temperature, crude tactile, tickle and itch
sensations, and cross to the opposite side shortly after entering the spinal cord. They terminate at
several levels of the brain stem and in the thalamus.
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Most of the afferent fibers of the somatosensory pathways terminate in the ventrobasal complex
of thalamus. The complex is formed by the ventral posterolateral nucleus (VPL), in which the
medial lemniscal fibers end; the ventral posteromedial nucleus (VPM), in which the fibers from
trigeminal nuclei terminate; and the posterior nuclei, where some fibers from the anterolateral
system project. In addition to VPL and VPM, some spinothalamic fibres are also relayed to the
intralaminar nuclei. From VPL and VPM the third-order nerve fibers project to the cortex. VPL
and VPM receive afferents also from other parts of the thalamus, such as the reticular nucleus,
which modulates the signal flow via VPL and VPM to the cortex. (Kahle et al., 1986)
All relay nuclei along the somatosensory pathway preprocess the sensory information and
determine whether it is transmitted further towards the cerebral cortex. Divergent presynaptic and
convergent postsynaptic connections are repeated in each of the relays, so that sporadic activity
and noise is filtered out, whereas strong sequences of repetitive activity from individual sensory
fibers and activity transmitted simultaneously by multiple receptors may be enhanced and carried
towards the brain. For example, processing in the relay nuclei may enhance the contrast of the
sensory information. (Kandel et al., 2000)
3.2.2. Cortical Somatosensory Areas
Several cortical areas participate in the processing of somatosensory information. The primary
somatosensory area (SI) receives input from VPL and VPM. The SI lies immediately behind the
central sulcus, and comprises Brodmann areas 3a, 3b, 2 and 1. Areas 3b and 1 mainly receive
information from cutaneous receptors, while areas 3a and 2 mainly receive proprioceptive
information from muscles and joints. These four areas of SI are extensively interconnected, so
that both serial and parallel processing are involved in higher-order elaboration of sensory
information. The cortical connections show laminar specificity so that layer IV receives most of
the input from the thalamus, whereas layer VI projects back to the thalamus and layer V projects
to other subcortical structures. Layers II and III project to other cortical regions.
The secondary somatosensory area (SII) is buried deep in the lateral sulcus, in the parietal
operculum near the SI face area. Its main input comes from VPL, VPM and SI. In addition, the SI
and SII areas send fibers to several other cortical areas, including the posterior parietal association
cortex (PPC, Brodmann areas 5 and 7), as well as the primary motor cortex and premotor areas
(Brodmann areas 4 and 6, respectively). (Kandel et al., 2000)
3.3. NEURAL BASIS OF EVOKED RESPONSES
An evoked response means a momentary change in the electrical activity of the brain caused by
an external stimulus. Evoked responses can be measured with EEG and MEG. Stimuli of
auditory, visual and somatosensory modalities are most often used to evoke the responses. For
example, SEPs and SEFs provide the means to non-invasively study the somatosensory system of
the peripheral and central nervous systems.
Synaptic activity in cortical pyramidal neurons is believed to be the major contribution to the
signal detected by EEG and MEG. Neurons communicate through axodendritic, axosomatic and
axoaxonal synapses that can be either inhibitory or excitatory. Most of the excitatory synapses lie
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on dendrites, and the majority of inhibitory synapses are localized on the cell body or at the base
of the axon, where the action potentials are generated, and can thus be most effectively
suppressed (Kahle et al., 1986). When a thalamocortical afferent synapses on a dendrite near the
soma of a neuron on layer IV, the discharge of synaptic vesicles leads to changes in the
membrane potential of the postsynaptic neuron (Figure 1). In the case of excitatory synapses,
current flows into the postsynaptic cell dendrite and the normally negatively charged interior of
the cell becomes less negative with respect to the extracellular side, in other words, is depolarized
(e.g., Kandel et al., 2000). The site of generation of the so-called excitatory postsynaptic
potential, EPSP, is called a current sink. The current loop is closed when the current flows along
the dendrite and back out across the membrane at other sites, creating a current source. If the
current is measured with an extracellular electrode at the site of the generation of the EPSP (the
sink), a current flowing away from the electrode into the cytoplasm would be detected as a
negative deflection. In contrast, an extracellular electrode near the source would have the opposite
polarity.
One postsynaptic current forms a current dipole in the order of 20 fAm (Hämäläinen et al., 1993),
and is thus too small to be detected from outside the brain. However, numerous synapses, both
inhibitory and excitatory, are active simultaneously on neurons, and synchronous activation of
tens of thousands of neurons can in favourable conditions exceed the detection threshold.
Because the apical dendrites of pyramidal neurons are aligned in parallel, summated postsynaptic
currents flowing in them form so-called electrically open fields, which can be detected at a
distance, e.g., by an EEG electrode or an MEG sensor. In contrast, the dendrites of interneurons
are oriented randomly and thus the electric fields of PSPs in them tend to cancel each other, and
are not detected in EEG or MEG. The detection of activation is facilitated by the temporal
summation of PSPs usually lasting tens of milliseconds. Action potentials involve higher voltage
fluctuations than PSPs, but still do not contribute significantly to the measured cortical magnetic
fields, mainly because they last only for about 1 ms, and are thus poorly temporally summated.
Furthermore, an action potential is associated with two current dipoles in opposite directions and
thus forms a current quadrupole, whose magnetic field decreases with distance much more
rapidly than that of a dipole.
The exact nature of the activated sources can not be deduced from the signals measured from
outside the head. For example, an inhibitory postsynaptic potential, IPSP, causes the current to
flow out of the postsynaptic neuron, and thus the membrane potential change is opposite to the
one created by an EPSP at the same location. Thus, EPSPs in superficial layers and IPSPs in
deeper layers both appear as negative potential deflections when measured at the cortical surface.
Figure 1. A schematic drawing of a
cortical neuron that receives an
excitatory afferent. The following local
depolarization of the postsynaptic
membrane forms the current sink. A
current flowing along the apical dendrite
closes the current loop. From a distance,
the current flowing inside the dendrite
looks like a current dipole. One should
note, however, that the direction of the
current would be opposite if the synaptic
input would be to more superficial part
of the dendrite.
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3.4. MAGNETOENCEPHALOGRAPHY (MEG)
The following description of the MEG technique is based mainly on the extensive review by
Hämäläinen et al. (1993).
3.4.1. Basic Concepts
MEG records the weak extracranial magnetic fields generated by neuronal currents. These
currents are detected with an extremely sensitive piece of equipment, called the SQUID
(Superconducting QUantum Interference Device). The SQUID is a superconducting ring,
interrupted by one or two Josephson junctions, which operates at temperatures near absolute zero.
A flux transformer, consisting of pickup, compensation and signal coils, detects a change in the
external magnetic field and converts it into an electric current. Because of mutual inductance
between the SQUID and signal coil, the flux sensed by the SQUID is proportional to the original
change in magnetic field detected by the pickup coil.
In the analysis of MEG signals, the head is usually approximated by a spherically symmetric
conductor, since over many regions of interest the brain does not differ significantly from a
sphere. This simplifies the calculation of the sources, since radial primary currents within a
sphere do not cause external magnetic fields. Because currents in the apical dendrites mainly flow
perpendicularly with respect to cortical surface, currents in the walls of cortical sulci are expected
to be tangential, and thus detected with MEG. Because the conducting properties of the tissues
between the active brain source and the measurement sensor do not affect the magnetic field
patterns, the localization of these sources underlying the cortical tangential currents is less
problematic than in EEG.
3.4.2. Recording Equipment
In the present study, measurements were performed in the BioMag Laboratory at the Helsinki
University Central Hospital using a Neuromag-122 system (Neuromag Ltd., Helsinki, Finland).
The device consists of 122 measuring sensors, positioned in a helmet-shaped configuration
(Ahonen et al., 1993). The sensors are planar gradiometers shaped as figure-of-eight and arranged
in 61 pairs, each of which measures two orthogonal derivatives of the radial component of the
magnetic field. The planar gradiometers are sensitive to nearby sources and detect the maximum
signal just above the source. Because the measured magnetic fields are extremely weak, in the
order of 50–500 fT, which is about 1/109–1/108 of the earth’s magnetic field, the measurement
device is situated inside a magnetically shielded room.
3.4.3. Source Estimation
The major challenge in the evaluation of the MEG data is the so-called inverse problem, i.e., how
to use the data measured from outside the head to estimate the sources inside the brain, since an
infinite number of primary current distributions can produce a given magnetic field measured
from outside the brain. Thus, a priori constraints are needed in order to determine the source
distributions (Ilmoniemi, 1991). In most MEG measurements, these constraints can be defined on
22
the basis of knowledge of the underlying physiological phenomena, or, e.g., by using structural
MRI to restrict the areas from which activation can arise.
The simplest and most often used source model for MEG studies is the equivalent current dipole
(ECD). The ECD represents the location, orientation, and strength of the underlying source, and
is calculated by fitting the predicted and measured magnetic field patterns in the least-squares
sense. Other analysis methods, which have the advantage of not making as strong a priori
assumptions of the current distribution, include for example the minimum-norm estimate
(Hämäläinen and Ilmoniemi, 1994) and L1-norm minimum-current estimate (Uutela et al., 1999).
3.4.4. Comparison of MEG with EEG
Both MEG and EEG are noninvasive and painless techniques to measure synchronous neuronal
activation in millisecond time scale. The primary currents causing the signal are the same for
MEG and EEG, but the electric and magnetic field patterns, and thus the directions of highest
sensitivity are orthogonal with respect to each other. MEG detects only tangential dipoles,
whereas also the radial ones are detected with EEG. However, since approximately 2/3 of the
human cortex is embedded in fissures, including large proportions of the primary cortical
projection areas, many of the human cortical sources are accessible to MEG. Furthermore,
especially in the case of many simultaneous active sources, the analysis of the source location is
easier in MEG than in EEG, because the algorithms only have to take tangential currents into
consideration.
MEG is not influenced by the changes of conductivity between the active brain source and the
measuring device. This makes MEG field patterns more spatially constrained than EEG potential
distributions, which means that an easier and more precise estimation of the underlying source
location and strength can be carried out with MEG than with EEG.
With EEG, measuring electrodes can be placed along the afferent pathway and impulse
transmission followed at many sites from periphery to cortex, whereas the MEG helmets mostly
measure cortical activity. However, in MEG measurements, no reference electrodes are needed.
3.5. SOMATOSENSORY EVOKED MAGNETIC FIELDS (SEFS)
3.5.1. SEFs in Normal Subjects
General
The ability to measure SEFs over the SI area with a SQUID device was first demonstrated in
1978 by Brenner and colleagues. These first responses, brought about by a steady-state paradigm
and recorded with one measuring channel, succeeded to demonstrate that SEFs to thumb and little
finger stimulation originate from different locations in SI (Brenner et al., 1978). Since then MEG
devices have evolved to whole-head covering systems that typically incorporate more than one
hundred measurement channels (Figure 2), and the somatotopical organization of SEFs along the
postcentral cortical strip has been proven by several researchers (e.g., Hari et al., 1984, 1993;
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Okada et al., 1984; Huttunen et al., 1987a; Narici et al., 1991; Rossini et al., 1996; Nakagawa et
al., 1998; Nakamura et al., 1998; Ishibashi et al., 2000).
SEFs from the Contralateral SI
The strongest and earliest cortical activation after peripheral sensory stimulation is seen at the
contralateral SI. After electrical median nerve stimulation, usually four deflections (N20m, P35m,
N45m and P60m) can be distinguished. The precise area from which the earliest cortical SEFs
arise, is believed to be the posterior bank of the central sulcus, mainly area 3b (Wood et al., 1985;
Huttunen et al., 1987a; Tiihonen et al., 1989; Ishibashi et al., 2000). The pyramidal neurons in
area 3b are located parallel to each other, perpendicular to the cortex. Earliest activation of area
3b occurs approximately 20 ms after peripheral stimulation of the median nerve, when the
thalamocortical afferents synapse on the basal dendrites, resulting in current flow in the apical
dendrites towards the superficial part of the cortex, which is seen as a forward pointing dipole on
magnetic field contour maps. This generation model of the earliest deflection, N20m, was
suggested already in the early studies with combined MEG and EEG measurements (Wood et al.,
1985), and is now widely accepted. A recent study further analyzed the evolution of the N20m
activity, and found that the underlying source moves in a direction orthogonal to the apical
dendrites, parallel to the surface of the posterior bank of the central sulcus (Hashimoto et al.,
2000).
The generator mechanisms of SI deflections following N20m are still disputed. Over the years,
several lines of evidence have suggested that the cortical populations generating P35m differ
from the N20m generators. First, the location of the P35m ECD is slightly different from the
location of the N20m ECD (Huttunen et al., 1987a; Allison et al., 1989; Tiihonen et al., 1989;
Wikström et al., 1996). In some studies, the different location of P35m has been interpreted as
evidence that P35m is at least partly composed of activation generated in the anterior bank of
central sulcus (Huttunen et al., 1987a; Tiihonen et al., 1989; Baumgartner et al., 1991;
Kawamura et al., 1996). However, it was also suggested that this anterior location of P35m could
be a modelling error rather than a true difference in location (Huttunen, 1997). In addition, it is
Figure 2. The 122-
channel somatosensory
evoked responses to
right median nerve
stimulation. The greatest
activation is seen over
the left hemisphere, on
the contralateral SI hand
area.
Left                                                                     Right
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possible that the SI areas 3a, 1 and 2, which also receive somatosensory input, may have some
contribution to SEFs. It was suggested that sometimes tangential components could be detected
from areas mainly giving rise to radial dipoles (Tiihonen et al., 1989; Baumgartner et al., 1991).
A recent study of finger II, III and V stimulation suggested that, unlike the N20m and P60m, the
P35m ECDs do not demonstrate somatotopy, but are instead located in clusters, probably in area
1 (Ishibashi et al., 2000). In addition, the different interstimulus interval (ISI) dependencies of
N20m and P35m have been interpreted as evidence that P35m is activated by polysynaptic
pathways (Tiihonen et al., 1989), and also that P35m reflects inhibitory postsynaptic potentials
(Wikström et al., 1996).
SEFs from SII
The characteristic feature of bilateral activation of the parietal opercular sources after
somatosensory stimulation was shown using MEG already in the early 1980s (Hari et al., 1983,
1984). The exact location of SII in humans is probably in the upper bank of the lateral sulcus
(Sylvian fissure), just below the head representation of SI. Although at least two different loci of
somatosensory activation seem to exist within the human perisylvian cortex (Mima et al., 1997;
Korvenoja et al., 1999), the opercular responses measured with MEG have been traditionally
designated as emanating from the secondary somatosensory cortex (SII).
The SII SEFs demonstrate somatotopic arrangement, but the differentiation between body parts is
not as clear as in SI SEFs (Hari et al., 1990, 1993; Maeda et al., 1999). Although the field
patterns of the contralateral (SIIc) and ipsilateral (SIIi) secondary somatosensory responses are
similar, the SIIc responses seem to be stronger (Hari et al., 1983, 1984; Mima et al., 1998a) and
peak earlier (Forss et al., 1994a; Simões and Hari, 1999; Wegner et al., 2000) than the SIIi
responses.
Usually, the onset of SII activation has been reported to be after 60–80 ms (Hari et al., 1984;
Mauguière et al., 1997b; Wegner et al., 2000). However, two studies have suggested that SII
activity may already begin about 20–30 ms after stimulation (Karhu and Tesche, 1999; Korvenoja
et al., 1999).
Other Activated Areas
Activation of the above-described SI and SII areas account for most of the SEFs. However,
multidipole modelling techniques have shown that at certain time periods, additional sources are
needed to satisfactorily explain the data. The presence of a posterior parietal cortex (PPC) source
when the median nerve was electrically stimulated was described by Forss et al. (1994a). This
source is most active between 70–110 ms, but the activation range across individual subjects can
be 46–200 ms (Mauguière et al., 1997b). Although PPC has mainly been described as a
contralateral response (Forss et al., 1994a; Wikström et al., 1996; Mauguière et al., 1997b) right-
and left-side air-puff stimulation consistently activated the right hemisphere PPC (Forss et al.,
1994b).
Electrical stimulation of the median nerve has also demonstrated activation of an ipsilateral SI
source (Korvenoja et al., 1995), as well as bilateral sources in the ipsi- and contralateral
midfrontal or inferior frontal gyri (Mauguière et al., 1997b). However, the ipsilateral SI was seen
in only 5 out of 10 subjects, peaking within a time range of 90–290 ms, with a rather weak
maximum strength. The sources for frontal activation, seen in 5 out of 8 subjects studied, were
active between 65 and 200 ms, and showed rather scattered localization across subjects.
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Yet another novel source, originating from the mesial cortex and peaking at 120–160 ms, was
demonstrated by its enhancement to selective attention towards both median and ulnar nerve
stimulation (Forss et al., 1996).
Interhemispheric Differences
The waveforms of SEFs, at least during the first 100-ms period, within one subject seem to be
similar and stable on both hemispheres (Tecchio et al., 2000), suggesting thus that dissimilar
waveforms from the two hemispheres could have pathological significance in patients. However,
another study on healthy subjects demonstrated that although the response strengths from the two
hemispheres are often symmetric, in some subjects there may be marked differences (Wikström et
al., 1997). The contralateral SI responses have been found to be stronger in the left than in the
right hemisphere (Rossini et al., 1994), but these differences were not confirmed in another study
(Wikström et al., 1997). In addition, although there may be no systematic statistical differences
between left and right hemisphere SI ECD locations in all populations (Rossini et al., 1994),
within individual brains, the cartesian coordinates expressing the locations of the sources may
differ between the two hemispheres. In fact, a careful analysis of the SEFs with a whole head
covering MEG device showed that the interhemispheric differences in the cartesian coordinates
within an individual can be in the order of few centimetres, although at group level the mean is
below 5 mm (Wikström et al., 1997).
It has also been suggested that compared with right hemisphere SII responses, left hemisphere SII
responses are stronger (Forss et al., 1994a), become active earlier (Forss et al., 1994b) and locate
more posteriorly (Simões and Hari, 1999; Lin et al., 2000). However, in other studies, no
interhemispheric differences in the SII responses have been observed (Wikström et al., 1997;
Wegner et al., 2000), and it has also been found that the SII response latencies are longer in the
left than in the right hemisphere (Simões and Hari, 1999).
Influence of Recording Parameters
In clinical situations, it is usually beneficial to optimize the protocol so that the measurement
session is short and comfortable for the patient, and yields repeatable and reliable results. Since
averaging a sufficient number of responses to reach an adequate signal-to-noise ratio is essential,
the ways to shorten the recording time are mainly to reduce the stimuli interval times or to
stimulate different nerves alternately or even simultaneously in a single run. However, all these
factors significantly change the morphology, and especially the strengths of the responses, as
discussed below. Nevertheless, the locations of the ECDs seem to be very stable, since a change
of ISI (Wikström et al., 1996; Mertens and Lutkenhöner, 2000), stimulus intensity, frequency or
attention (Mima et al., 1998a), or interfering tactile stimulation (Naka et al., 1998) do not seem to
affect the ECD locations. However, one study reported that sources activated by air-puff
stimulation were located deeper in the wall of the central sulcus than those activated by electrical
stimulation (Rossini et al., 1996), but this finding was not validated by others (Forss et al.,
1994b).
Stimulus Type
Electrical stimulation of mixed nerves is the most used stimulus method. It has the advantage of
producing clear and strong responses, but the disadvantage of the simultaneous activation of a
large number of fibers that potentially have different conduction velocities. More natural
methods, such as air-puff stimulation that selectively activates cutaneous mechanoreceptors, or
electrical stimulation of the sensory part of the nerve, can be used, but the resulting SEFs over SI
areas are weaker and peak at longer latencies (Huttunen, 1986; Kaukoranta et al., 1986; Huttunen
et al., 1987b; Forss et al., 1994b; Rossini et al., 1996). However, later parts of the responses,
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namely SII(c) and PPC, do not seem to be smaller as a result of air-puff stimulation than of
electrical stimulation (Forss et al., 1994b).
Stimulus Intensity
Generally, in studies of somatosensory evoked responses, a stimulus exceeding the motor
threshold but being below the pain threshold, is believed to cause reliably repeatable responses
(e.g., Huttunen, 1995). However, recent studies have demonstrated that the SEFs may be
influenced by the stimulus intensity even above the motor threshold. The strength of N20m but
not P35m, was reported to increase when the stimulus intensity was changed to cause vigorous
movement instead of a small thumb twitch (Jousmäki and Forss, 1998). Similar results of up to a
two-fold increase in the N20m amplitudes in some subjects were obtained when stimulus strength
was increased from motor threshold to 1.5 times the motor threshold (Tsutada et al., 1999).
However, when the stimulus intensity was further increased to twice the motor threshold the
N20m amplitudes were not increased. The latency of N20m was not affected when stronger
stimuli were applied, whereas the P35m latency shortened (Jousmäki and Forss, 1998). There
were no differences in the strengths of SII and PPC responses when the strength of a stimulus
above motor threshold was further increased, however, the SII latencies were shorter than in a
situation when stimulus was just above sensory threshold.
Interstimulus Interval
Tiihonen and colleagues (1989) noticed that increase of ISI from 0.2 to 0.5 s increases the
amplitude of P35m more than that of N20m. In fact, between ISIs of 0.3–5 s, the strength of
N20m is rather stable, whereas P35m strength is stable at longer ISIs (from 3 to 5 s), but
decreases with the shortening of ISI (Wikström et al., 1996). The other SI responses are also
strongly ISI dependent: the N45m dominates the responses at short ISIs (below 1 s), whereas the
P60m attenuates towards the shorter ISIs. The change of ISI has not been reported to change the
ECD locations (Wikström et al., 1996; Mertens and Lutkenhöner, 2000).
The strengths of the later responses are strongly influenced by the interstimulus interval. Even
though the SII responses can be recorded with ISIs as short as 1 s (Wikström et al., 1996), it has
been shown that in some subjects the SII response may become stronger up to ISIs of 8 s (Hari et
al., 1993). In other studies, the strengths of SII and PPC responses increased when ISI was
increased from 1 to 3 s, but remained stable when ISI was further increased to 5 s (Forss et al.,
1994a; Wikström et al., 1996).
Alternating, Unilateral or Bilateral Stimulation
Stimulation of the median nerve 20–120 ms after applying a conditioning stimulus on the
ipsilateral median or ulnar nerves causes attenuation of most of the SI responses (Huttunen et al.,
1992). However, the SI responses remain unchanged if the prior stimulus is on the tibial or
contralateral median nerves. Furthermore, the early SI responses seem to be unaffected by
simultaneous bilateral stimulation of the median as well as the tibial nerves (Shimojo et al., 1996,
1997), and also by alternating stimulation of the median nerves with ISI of 3 s (Wegner et al.,
2000). Thus, it seems that the neural populations causing the early onset SI activity do not have
bilateral receptive fields, but are partially the same for ulnar and median nerves that have adjacent
innervation areas peripherally (Huttunen et al., 1987a, 1992). Similar findings of greater
occlusion and/or surround inhibition from adjacent fingers than from fingers further apart, was
suggested by Ishibashi and colleagues, since simultaneous stimulation of the II and III fingers
resulted in greater interaction of N20m and P60m deflections than did stimulation of fingers II
and V (Ishibashi et al., 2000).
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Thus, alternating or simultaneous bilateral stimulation of the median nerves can be chosen when
the purpose is to study contralateral SI responses. However, when attempting to study responses
outside the SI area, unilateral stimulation of the median nerves may be advisory, since the SII
responses are attenuated by both bilateral (Shimojo et al., 1996, 1997) and alternating stimulus, at
least when the interstimulus interval is 3 s or shorter (Wegner et al., 2000). A long-lasting
modulation of SII activity by prior stimulation was further supported by a recent study that
demonstrated that when stimuli to median nerves were presented in pairs of two, the response
latencies for the second stimulus were always longer than for the first, despite of the order of the
stimulated nerves in the pair (Simões and Hari, 1999).
Modulation of the Responses by Behavioural Factors
Active attention does not seem to affect the SI responses, whereas the SII (Hari et al., 1990;
Mauguière et al., 1997c; Mima et al., 1998a) and mesial cortex responses are increased by active
attention to the stimulus (Forss et al., 1996). There is some evidence to suggest that SII response
strengths could be more vulnerable to reduced vigilance than SI responses, since the SII responses
strengths were smaller at the end of the session than early in the session (Wegner et al., 2000).
Interfering tactile stimuli may cause reduced response amplitudes from both SI (Naka et al.,
1998) and SII cortices (Huttunen et al., 1996). In contrast, active movement of fingers,
contraction of thenar muscles or deltoid muscle on the same side as the median nerve stimulation
results in increase of the SII response strengths (Huttunen et al., 1996; Lin et al., 2000). However,
the SII response strengths are reduced by contraction of the masseter and the ipsilateral tibial
muscle (Lin et al., 2000).
Effect of Maturation and Ageing
The development of SEFs in childhood and adolescence is poorly characterized, because only
occasional SEFs of children have been published (Paetau et al., 1994). The only systematic study
of the effect of age on SEFs was conducted on adults, and demonstrated that in the age range of
20–73 years, the N20m strength correlates positively with age, whereas the strengths of P35m and
P60m do not (Huttunen et al., 1999). However, according to studies on SEPs in children, several
developmental changes in the SEFs can be expected with age. First, the latencies of the cortical
SEP components are affected by two opposing factors during development. The growth of the
body increases the lengths of the pathways and should thus prolong the latencies, while
myelination and maturation should decrease the latencies by accelerating the conduction. In fact,
in SEP studies, the latencies of the cortical components initially decrease until about the age of 3
years (Bartel et al., 1987; Taylor and Fagan, 1988; Müller et al., 1994), but after that, the
latencies become longer with increasing body size (Zhu et al., 1987; Taylor and Fagan, 1988).
However, judging from the CCT, which measures the time the impulse travels within the central
nervous system, maturation of the afferent central pathways is not completed during the first 5–10
years (Bartel et al., 1987; Taylor and Fagan, 1988; Müller et al., 1994; Boor et al., 1998; Boor
and Goebel, 2000), or perhaps even during the first decades of life (Hume et al., 1982; Allison et
al., 1983, 1984). It must also be noted that the maturation and development may not affect all
components of the cortical responses similarly (Taylor and Fagan, 1988). In addition, some
differences that exist in adults may not be seen in children. For example, the latencies in children
may be unaffected by gender (Allison et al., 1983, 1984; Mattigk, 1991).
In addition to the above-mentioned changes in latencies, the SEP waveforms and amplitudes are
also affected by development (Desmedt et al., 1976; Taylor and Fagan, 1988; Kakigi and
Shibasaki, 1991; Mattigk, 1991). Also changes in the stimulus parameters, like the interstimulus
interval, can have a stronger effect on the evoked responses in children of different ages (Araki et
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al., 1999). In clinical SEP recordings, lower stimuli rates are recommended to be used in infants
than in adults.
3.5.2 SEFs in Patients with Central Nervous System (CNS) Disorders
Recording of SEPs is routinely used in clinical studies of patients with different cerebral diseases
(Chiappa, 1989). Alterations of SEPs are seen, e.g., with impaired conduction properties of
peripheral or central parts of the somatosensory pathways. However, although latency
abnormalities along the afferent pathways are readily characterized with SEP techniques, the
interpretation of slightly altered response amplitudes in SEP recordings is compromised by the
distortion of the electric fields by the conductivities of the intervening media. Thus, it seems that
recording SEFs could be advantageous in certain clinical situations, which require precise source
localization or characterization of the response amplitudes. Indeed, the most established role of
MEG in a clinical setting is its use in presurgical evaluation, where SEFs are used to locate the
central sulcus (e.g., Alberstone et al., 2000; Kumabe et al., 2000; Mäkelä et al., 2001). In
addition, MEG has successfully been employed to determine the sources of epileptic activity (e.g.,
Minassian et al., 1999; Paetau et al., 1999; Sobel et al., 2000).
Another interesting application of MEG has been the study of the magnetic counterparts of the
giant SEPs, seen usually in patients with progressive myoclonus epilepsy (PME; Rothwell et al.,
1984; Obeso et al., 1985; Shibasaki et al., 1985; Berkovic et al., 1991). The short-latency SEFs,
both normal and enlarged, have been shown to be generated at SI in patients with familial PME
(Uesaka et al., 1993), in patients with PME of the Unverricht-Lundborg type (ULD; Karhu et al.,
1994; Forss et al., 2001), and in patients with cortical myoclonus of various origins (Mima et al.,
1998b). The most significantly enlarged SI deflection in all these patients was the P35m, whereas
the N20m was reported normal or slightly enlarged in some patients. N45m deflections, normal or
enhanced, were detected in two of the studies (Karhu et al., 1994; Mima et al., 1998b). In
addition to being enlarged, P35m was also reported to peak earlier than in normal controls
(Uesaka et al., 1993; Karhu et al., 1994; Forss et al., 2001). Abnormal late “repetitive SEFs” at
200 ms from area 3b were observed in three patients with cortical myoclonus (Mima et al.,
1998b).
Activation of brain areas outside contralateral SI in PME patients was noticed in the two studies
conducted with whole-head covering devices. Ipsilateral activity, most likely from SI, was
demonstrated in several patients (Mima et al., 1998b; Forss et al., 2001), and it has been
suggested that the appearance of the ipsilateral SI would be associated with the increased risk of
generalized seizures. However, SII responses, which were searched for in three of the studies,
were found in only two of the altogether 11 ULD patients and in one of the cortical myoclonus
patients (Mima et al., 1998b; Forss et al., 2001). In these patients, the SII responses were not
abnormally strong.
In paediatrics, MEG has been used in one study to examine SEFs in patients with benign rolandic
epilepsy (Kubota et al., 2000). Until the studies described in this Thesis, no data has been
available on SEFs in paediatric patients with degenerative brain disorders such as NCL.
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4. AIMS
The general aim of this Thesis was to clarify the mechanisms of deterioration of the functioning
of the neuronal networks in NCL. We focused on the somatosensory system and recorded SEFs to
median nerve stimulation in three genetically different NCL forms, JNCL, NES and vLINCLFin.
In order to compare the SEFs in patients with adequate control data, an age-matched control
group consisting of healthy subjects was measured for each study. The degree of neuronal
dysfunction caused by the disease, demonstrated by the alterations in SEFs, was related to the
genotype, clinical findings and the structural brain MRI alterations in individual patients. The
specific aims of the Studies I–IV were:
I To examine somatosensory cortical excitability in JNCL by characterizing how the
progression of the disease affects the median nerve SEFs
II To evaluate the effect of the genotype of 10 compound heterozygous patients with JNCL
to their clinical, neurophysiological and neuroradiological phenotype
 
III To study somatosensory cortical excitability in patients with NES and to compare their
brain MRI findings with the known findings in JNCL and vLINCLFin
 
IV To investigate excitability of the primary and secondary somatosensory cortex in patients
with vLINCLFin
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5. METHODS
5.1. STUDY DESIGN
Altogether 33 patients, including 24 with JNCL, 4 with NES and 5 with vLINCLFin, participated
in the study (Table 2). SEF recordings were performed on 31 of the patients, 25 of whom also
underwent structural brain MRI imaging. At the beginning of these studies, the mutations of
patients with JNCL were not yet known and thus Study I included patients with different
genotypes. Here, the patients with JNCL are presented in two groups. JNCL–I group includes 14
patients homozygous for the major 1.02-kb deletion, including 6 novel patients in addition to the
8 homozygous patients originally included in Study I. JNCL–II group includes the 10 patients
who are compound heterozygous for the major 1.02-kb deletion and for another CLN3 mutation
(Study II).
Table 2. Control subjects and patients
Controls JNCL–I
(homozygous for the
1.02-kb deletion)
JNCL–II
(compound heterozygous
for the 1.02-kb deletion and
another CLN3 mutation)
NES vLINCLFin
Study I–IV I and unpublished II III IV
No. subjects 27 14 10 4 5
SEFs 27 14 8 4 5
Age range* 6.5–44.0 6.4–21.0 7.3–30.7 26.2–43.4 8.8–16.7
Male/female 13/14 7/7 6/4 2/2 3/2
MRI* 25 12 5 4 4
* at the time of SEF measurements
The study protocol was approved by the ethical committee at the Hospital for Children and
Adolescents, University of Helsinki. Informed consent was obtained from all subjects and/or their
parents. The healthy control subjects over 18 years gave their informed consent, in younger
subjects and all patients the consent was asked also from their parents or legal guardians. The
purpose of these investigations was considered important and the results could not be achieved in
any other way except by studying these patients. None of the examinations performed (clinical,
MRI and SEF studies) caused pain or are considered harmful to the subjects. No anaesthetics
were used.
5.2. PATIENTS
The 24 patients with JNCL and 5 patients with vLINCLFin were recruited by a paediatric
neurologist (P. Santavuori) from the outpatient clinic of the Department of Paediatric Neurology
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at the Hospital for Children and Adolescents, University of Helsinki during years 1995–1998.
Only patients older than 6 years were considered eligible to participate. All the patients with
JNCL and vLINCLFin had been clinically followed up by P. Santavuori for 3–21 years. All
patients with JNCL had vacuolated lymphocytes and typical ophthalmologic findings of retinal
and macular degeneration (Santavuori, 1988). Fifteen patients with JNCL represented the only
case in their family, 3 patients had one affected sibling who also participated, and one had two
affected siblings who participated. In patients with JNCL, rectal biopsy had been performed on
the oldest affected sibling in the family (altogether 15 patients) and showed the characteristic
fingerprint profiles and/or curvilinear bodies (Rapola, 1993). At present, all patients have
genetically confirmed diagnoses. Fourteen of the patients were compound heterozygous for the
major 1.02-kb deletion that removes exons 7 and 8 from the transcript (Järvelä et al., 1997). In 4
of the compound heterozygous patients, the screening for the major 1.02-kb deletion and
delineation of mutations on the other chromosome was reported earlier (The International Batten
Disease Consortium, 1995; Munroe et al., 1997), whereas in six of the compound heterozygous
patients the other CLN3 mutation was described in Study II. The mutations and clinical course in
relation to phenotype-genotype correlation of all the vLINCLFin patients was reported earlier
(Holmberg et al., 2000). In patients with vLINCLFin, the rectal or skin biopsy showed the
characteristic fingerprint profiles or fingerprint profiles and curvilinear bodies. None of the
patients included in the study had other neurological diagnoses.
For Study III, the four patients with NES were recruited by an invitation letter that was distributed
by a paediatric neurologist (A. Hirvasniemi). All patients that participated belong to the original
NES patient series published earlier (Hirvasniemi et al., 1994, 1995). They all had genetically
confirmed diagnoses (Ranta et al., 1999), and a typical clinical picture, neurophysiological and
imaging findings. Two of the patients were siblings.
Before each SEF measurement, a paediatric neurologist (P. Santavuori) clinically examined all
patients and recorded their motor performance, balance, coordination, speech, visual performance
and history of epilepsy, as described in Santavuori et al. (1988). The clinical course of the
patients with JNCL was determined as classical, delayed classic or protracted. In homozygous
JNCL patients this classification was performed at the time of writing this Thesis. The phenotype
was determined classic if significant mental retardation (IQ level reduced by more than 10 points
from the time of diagnosis) had taken place before the age of 10 years and/or parkinsonian signs
emerged before the age of 15. Patients were determined to have delayed classic course if
significant mental retardation took place after 10 years of age and/or parkinsonian signs after 15.
Protracted JNCL was characterized in patients that had progressive visual loss at an early age, but
did not have mental and motor symptoms in the first two decades of life. The medication of the
patients, which included antiepileptic drugs, muscle relaxants and antioxidants (only patients with
JNCL), was unchanged during the several months prior to the measurements.
5.3. HEALTHY CONTROL SUBJECTS
The 27 control subjects were relatives or friends of the laboratory personnel. Seventeen of them
were younger than 19 years. All of the control subjects attended or had graduated from normal
school. None of them had a history of neurological illness or head trauma. Altogether 25 controls
underwent MRI. All controls from Studies I–IV are presented in Table 2 and in the Results
section of this Thesis. However, the patients’ values here and in each of the Studies I–IV were
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compared with those of specific age-matched control groups. However, because novel patients
with JNCL outside the original age range are included in this Thesis, all patients with JNCL are
compared to the control group used for Study II that consists of 19 of the control subjects (age
range 6–25 years, 8 males, height 125–187 cm). The control group for Study III consists of 8
subjects (age range 25–44 years, 5 males, height 156–191 cm), and that for Study IV consists of
10 controls (age range 8–16 years, 4 males, height 140–175 cm).
5.4. MEG Studies
5.4.1. Stimulation
The median nerves were stimulated in separate runs at the wrist with 0.2-ms constant-current
pulses. In 25 patients and 26 controls both the left (LMN) and right (RMN) median nerves were
stimulated. In 2 patients with vLINCLFin, in 4 patients with JNCL and in one control only the
RMN was stimulated, because of the poor condition of the patient or lack of cooperation. The ISI
was 2 s. The stimulus intensity was adjusted to be clearly above the motor threshold, but care was
taken not to cause discomfort to the subjects.
5.4.2. Recording
Measurements were performed in a magnetically shielded room (Euroshield Ltd., Finland) with
the 122-channel gradiometer system (Neuromag-122TM, Neuromag Ltd., Finland; Ahonen et al.,
1993) of the BioMag Laboratory at the Helsinki University Central Hospital.
Prior to measurements being taken, three position indicator coils were attached to the subject’s
head, and the coil locations with respect to anatomical landmarks were found with a 3D digitizer.
The preauricular points were used for the determination of the x-axis, which pointed to the right.
The y-axis was oriented towards the nasion and the z-axis pointed upwards. During the
recordings, the subject sat with his/her head inside the helmet-shaped sensor array. Healthy
control subjects and patients with NES watched a self-chosen video film; stories were read to the
other patients. All children and patients were accompanied by an adult during the measurements.
At the beginning of each measurement run, the exact head position inside the helmet was
determined by measuring signals from the three indicator coils. With this information, the MEG
and MRI coordinate systems were aligned during data analysis.
Two sets of 200 responses were averaged for each hand, except for patients with vLINCLFin with
whom 100–200 sweeps were taken. The signals were band-pass-filtered between 0.03 and 300 Hz
and sampled at 942 Hz. Epochs containing amplitudes exceeding 3000 fT/cm in the MEG
channels or 150 µV in the electro-oculogram were automatically discarded. An epoch lasted
350 ms, including a 50–100-ms prestimulus baseline.
5.4.3. Data Analysis
For the analysis of the SEF data, a spherical model of the head was used. The center of the sphere
was determined on the basis of the local radius of curvature near the SI, obtained from individual
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three-dimensional MPRAGE (Magnetization Prepared Rapid Acquisition Gradient Echo) images.
If the MPRAGE was not available (6 patients, 2 control subjects), the MRI of the subject with the
same diagnosis at the closest age was used.
In all studies, responses from the contralateral SI were analyzed. Local subsets of channels were
chosen to represent the magnetic field pattern over the region of interest. At the SI, a set of at
least 28 channels was used. Least-squares searches were then applied to the signals from these
subsets to determine the locations, orientations and strengths of the ECDs that best explained the
measured signals at the peaks of the main deflections (Hämäläinen et al., 1993). A 50 to 100-ms
time period before the occurrence of the stimulus was used as a baseline. The earliest negative
deflection, peaking at 15 to 30 ms, was defined to be N20m. The following positive deflection,
peaking at 25 to 50 ms, was defined as P35m. In most subjects, the next deflection was positive,
peaked at 50 to 140 ms, and was designated as P60m. In some subjects, the deflection following
P35m was negative, and was thus called N45m. It was included in the analysis in Study IV, and
only in the subjects in whom it crossed the baseline. The signals were in most cases digitally low-
pass filtered at 90 Hz before the analysis of the P60m. For each deflection, the ECD with the
greatest dipole moment was chosen, dipoles with a goodness-of-fit value over 80% were used
(Kaukoranta et al., 1986).
In Studies III and IV, some deflections generated from brain areas outside SI were also modelled.
Usually 18–24-channel subsets were chosen to cover the SIIc and SIIi areas, and the ipsilateral SI
in Study IV. In several subjects, the signal-space-projection method was used to eliminate the
contribution of the SI sources from the SII signals (Uusitalo and Ilmoniemi, 1997). A time-
varying multidipole model with one ECD from each activated brain area (usually P35m, SIIc and
SIIi) was calculated by taking into account signals from all channels: the locations and
orientations of the ECDs were kept constant and the strengths of the ECDs were allowed to vary
in order to best explain the whole data set.
The ECD locations were superimposed on the individual MRIs. The latency, location, orientation,
and strength (the dipole moment) of each ECD were compared with those of the normal controls
in each study. For the classification of ECD strengths, the upper limit for the normal value was
set at the control group mean + 2.5 SD. In the Result sections of this Thesis and in Studies III and
IV, the peak latencies of the patients’ deflections were considered abnormal if they fell outside
the range of latencies in the age-matched controls.
5.4.4. Statistical Analyses
In Study I, the significance of the differences in latency and locations of the ECDs between
patients and controls were evaluated using paired two-tailed t-tests. The sign test for matched
pairs was used to test the significance of the difference in the dipole moments between patients
and matched controls, because the response strengths were not normally distributed. The Kendall
tau coefficient was determined to test whether the dipole moments correlated with age.
For the results section of this Thesis, further statistical analyses were performed. Differences
between the deflections to RMN and LMN stimulation in healthy control and patient groups were
tested with Wilcoxon matched pairs test. In the other tests the values for right and left hands were
tested separately. The significance of the differences of the ECDs between controls and patients
with JNCL, as well the differences between the JNCL–I and JNCL–II groups were evaluated
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using Mann–Whitney U-tests. The Spearman R correlation coefficient (rS) was calculated to
determine if the latencies and dipole moments correlated with age.
5.5. MRI STUDIES (I–IV)
Altogether 25 patients and 25 controls underwent brain MRI examination (Table 2), in which a
sagittal T1-weighted 3D MPRAGE sequence, with time of repetition (TR) 9.7 ms and time of
echo (TE) 4 ms was taken to be used in the analysis of the SEF data. In addition, the MPRAGE
images of patients were used for the visual grading of the size of the corpus callosum (CC) and
cerebellar and cerebral atrophy (Autti et al., 1996). In Study III, in which the age range of the
subjects was 26–43 years, the size of cerebral cerebrospinal fluid (CSF) spaces were graded
according to the method developed by Salonen et al. (1997), in which standard images are used as
references to grade the size of CSF spaces into five categories (grade 1 represents the smallest
size of CSF spaces, grade 5 represents the most enlarged CSF spaces; grades are based on images
of neurologically healthy Finnish subjects (Salonen et al., 1997). In addition, in Study III, the
sagittal diameters of the mesencephalon, pons and medulla oblongata, as well as three diameters
of the CC, the area of CC and the brain area were measured from the midsagittal MPRAGE
image. The CC/brain area ratio was calculated. The normal values were established by measuring
the eight normal controls and calculating the normal mean ± 2 SD. These normal values were
found agree very well with those established previously (Laissy et al., 1993; Raininko et al.,
1994).
In Study III, a 5-mm T2-weighted spin-echo (TR 3000 ms, TE 85/14 ms) and FLAIR (fluid
attenuation inversion recovery, TR 9999 ms, TE 105 ms, inversion time (TI) 2500) axial images
were taken. The signal intensity ratios of deep grey and white matter structures were evaluated
according to method described previously (Autti et al., 1994). In addition, for Study II and this
Thesis, previous T2-weighted images of patients with JNCL (11 homozygous patients, age range
6–17 years, and 9 compound heterozygous patients, age range 6–32 years) were retrieved and re-
evaluated, and the signal intensity ratios of the deep grey matter structures were measured and
compared with established normal values (Autti et al., 1994).
In addition, in Study III, a post-mortem MRI with the same imaging parameters than in the living
NES patients was performed on one brain of a patient with NES who had died at the age of 38
(this patient was a sibling to the 40-year-old patient). The brain was cut into 1–2-centimeter slices
and stored in a formalin solution; before the MRI the brain was rinsed in distilled water. The
brain sections were imaged in a vessel containing distilled water and MnCl2 (Autti et al., 1997a).
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6. RESULTS
6.1. SEFS
6.1.1. Responses from the Contralateral SI (I–IV and unpublished data)
Healthy Controls
The response waveforms over the SI area contralateral to stimulation in the 27 control subjects
usually consisted of easily identifiable N20m, P35m and P60m deflections (Figure 3). An N45m
deflection was seen as an upward deflection between P35m and P60m, but was not included in
the analysis if it did not cross the baseline. The field patterns of the responses were dipolar: the
N20m ECDs pointed anteriorly and the P35m and P60m ECDs posteriorly. The responses were
well reproduced. The ECD locations corresponded to the known location of SI (Table 3).
Figure 3. The waveform of the contralateral SI response in a 10-year-old control subject showing the typical N20m,
P35m and P60m deflections to RMN stimulation. The isofield contour maps correspond to the peaks of the individual
SI deflections, the helmets are pictured from a left lateral view. The contour step is 50 fT, the dashed lines indicate
magnetic flux entering the head and solid lines magnetic flux exiting the head. The arrows denote the corresponding
ECDs with lengths proportional to the ECD strength.
Table 3. N20m and P35m ECD latency ranges and mean locations (standard deviations in parenthesis) in controls of
different age groups. Because there were no significant differences between the left and right hemispheres only data
to right median nerve stimulation is shown.
Age groups Height range Latency range Coordinates
[years] [cm] n [ms] x [mm] y [mm] z [mm]
N20m < 11 125–150 6 16–20 –35.7 (4.2)     4.6 (15.0)   92.9 (4.9)
11–15 148–170 5 18–20 –35.0 (8.2)   9.5 (8.5)   89.7 (8.1)
16–20 167–187 5 18–22 –36.1 (4.1) 14.1 (8.1)   97.6 (3.4)
> 21 156–191 9 18–24 –43.5 (6.2)   12.9 (11.8)   95.1 (3.8)
P35m < 11 6 30–33 –36.6 (6.5)    4.6 (17.2)   93.7 (6.7)
11–15 7 31–40 –33.8 (4.9) 13.5 (8.2)   96.4 (6.5)
16–20 5 31–39 –34.1 (4.1) 17.2 (7.4) 100.0 (3.8)
> 21 9 30–45 –38.5 (5.6)   10.5 (12.0)   99.1 (6.6)
0         100 ms
50 fT/cm
P60m
P35m
N20m
N20m                            P35m                               P60m      
N45m
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Within the individual control groups for the Studies I–IV the response strengths did not correlate
with age. The normal upper limits of the ECD strengths that were used for the different patient
groups are shown in Table 4.
Table 4. The mean (SD) values of the N20m and P35m deflections of the control groups for each study, and the
calculated upper normal limits for left and right median nerve stimulation.
Controls for
JNCL–I and JNCL–II
Controls for
NES
Controls for
vLINCLFin
Mean (SD)
[nAm]
Normal limit
[nAm]
Mean (SD)
[nAm]
Normal limit
[nAm]
Mean (SD)
[nAm]
Normal limit
[nAm]
N20m LMN 11.8 (4.8) 24 20.9 (6.8) 38 11.1 (6.1) 26
RMN 12.6 (3.4) 21 18.2 (6.8) 35 11.6 (3.8) 21
P35m LMN 38.3 (13.6) 72 42.4 (12.6) 74 38.1 (17.5) 82
RMN 32.8 (11.6) 62 42.6 (12.2) 73 33.0 (12.0) 63
Normal limit = the upper normal limit calculated from the normal mean ± 2.5 SD
However, when all controls, aged from 6 to 44 years, were grouped together it seems that the
controls over 25 years of age had stronger N20m responses than the younger subjects (Figure 4).
The ranges of N20m and P35m dipole moments were 5–31 and 11–79 nAm, respectively. The
dipole moments of N20m and P35m did not differ significantly between males and females.
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Figure 4. The N20m and P35m dipole moments as a function of age of normal controls to LMN and RMN
stimulation. The N20m strength correlated with age to both LMN (p = 0.02, rS = 0.52) and RMN (p = 0.047, rS =
0.39) stimulation. The P35m strength significantly correlated with age to RMN stimulation (p = 0.03, rS = 0.43).
The latency of N20m was longer in older (p = 0.003 and rS = 0.62 to LMN stimulation) and taller
subjects (p = 0.002 and rS = 0.64 to LMN stimulation, p = 0.047 and rS = 0.39 to RMN
stimulation). The latency of P35m was longer in older (p = 0.006 and rS = 0.53) and taller subjects
(p = 0.0008 and rS = 0.62) with left but not with right side stimulation. The N20m latency was
longer in the males than females to both LMN and RMN stimulation (p = 0.03 and p = 0.02,
respectively), which is most likely related to the greater height of the males.
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Patients
All patients demonstrated activity originating from the contralateral SI area. In patients with
JNCL or NES, the response waveforms were similar to those in controls, being typically
separable into N20m, P35m, and P60m deflections (Figure 5). In the older patients with JNCL,
the P60m deflection seemed to become less distinguishable. In contrast to the other patients, in
vLINCLFin, only the morphology of the two earliest deflections, N20m and P35m, was similar to
that in controls. An ensuing N45m deflection was seen in all patients with vLINCLFin, while the
P60m deflection was not detected (Figure 5). The responses in patients with vLINCLFin were
extremely strong compared with those of patients with JNCL or NES (Figure 6).
Figure 5. SI response waveforms from an 8.9-year-old patient with JNCL, a 26.2-year-old patient with NES, and a
12.3-year-old patient with vLINCLFin. The arrow depicts the stimulus. The response waveforms in JNCL and NES
were generally similar to those of controls, and consisted of N20m, P35m and P60m deflections. In all patients with
vLINCLFin, an N45m deflection followed the N20m and P35m deflections, whereas no P60m response was seen.
Figure 6. Dipole moments of N20m and P35m in different patient groups to both LMN and RMN stimulation. The
P35m dipole moment was always stronger than that of the N20m (note the different scales). Although the responses
were extremely strong in patients with vLINCLFin compared with the other groups, also the responses in patients with
JNCL were significantly stronger than in controls.
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With JNCL, the N20m responses were stronger than in the age-matched controls (p = 0.0006 and
p = 0.0001, respectively for LMN and RMN stimulation). This enhancement of N20m in patients
with JNCL correlated with age and thus with disease duration (Figure 7; p = 0.01 and rS = 0.59 for
LMN stimulation, and p = 0.000001, rS = 0.84 for RMN stimulation). Also the P35m responses in
patients with JNCL were stronger than in the controls (p = 0.001 and p = 0.0006, respectively for
LMN and RMN stimulation), but the P35m responses did not correlate with the age of the patient.
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Figure 7. The strengths of N20m and P35m in response to RMN stimulation as a function of age in patients with
JNCL. The enhancement of N20m was correlated with age to both LMN and RMN stimulation.
When the dipole moments were compared with the upper normal limits, most patients with JNCL
over the age of 11 years had abnormally strong responses (Table 5). The N20m strength was over
the upper normal limit more often than the P35m strength. There were no statistically significant
differences in the ECDs between the patients homozygous for the 1.02-kb deletion and compound
heterozygous patients.
Table 5. The percentage of abnormally strong responses in different patient groups. In parentheses, the number of
abnormal responses are given for all the responses evoked by left or right median nerve stimulation.
Age Deflection JNCL -I JNCL -II NES vLINCLFin
< 11.0 years N20m 0% (0/5) 0% (0/4) - 100% (2/2)
P35m 0% (0/5) 0% (0/4) - 100% (2/2)
> 11.0 years N20m 68% (15/22) 67% (6/9) 13% (1/8) 100% (5/5)
P35m 41% (9/22) 33% (3/9) 13% (1/8) 100% (5/5)
For patients with NES, the ECD strengths were generally within normal limits: the only
exceptions were a slightly enhanced N20m in one patient and a slightly enhanced P35m in
another patient. In vLINCLFin, all patients had enhanced N20m (range 70–287 nAm) and P35m
(range 180–611 nAm) deflections to both LMN and RMN stimulation; no age-related correlation
of the response strengths was observed. The N45m dipole moment in patients with vLINCLFin
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was also strong, being approximately of the same magnitude as that of N20m (range 127–
274 nAm, except for one deflection, which was 31 nAm).
The N20m, P35m and P60m ECDs were generally located in the vicinity of the hand
representation area of the SI. In patients with vLINCLFin, the location of the N45m ECD was
either the same as the ECD locations for N20m and P35m (in 3 hemispheres) or somewhat more
posterior (8–22 mm, 4 hemispheres).
With JNCL (Figure 8), the N20m latencies at the group level were slightly delayed compared
with those of normal controls’ (p = 0.0019 and p = 0.02, respectively for LMN and RMN
stimulation). Interestingly, when compared with the control values, the N20m latencies of
especially compound heterozygous patients with JNCL were delayed (Table 6). In all patients
with NES, the N20m latencies were normal, whereas in all patients with vLINCLFin, all the N20m
latencies were delayed.
Figure 8. The latency of N20m to RMN stimulation in controls and patient groups. The latencies were clearly delayed
in all patients with vLINCLFin. In JNCL, the latencies were slightly delayed at the group level, whereas in NES all
latencies were within normal limits.
The P35m latency did not differ significantly between patients with JNCL and the controls. Also
in NES and vLINCLFin patients, the P35m latencies were within the range of latencies of the
controls (with one exception, a patient with vLINCLFin with an abnormally short latency P35m).
However, the time interval between N20m and P35m was significantly shorter (p < 0.05) in
patients with JNCL than the controls. The same effect was especially pronounced in patients with
vLINCLFin, in whom the latency difference between N20m and P35m was shorter in all patients
(7–9 ms) compared with age-matched controls (12–24 ms).
Table 6. The percentage of abnormal N20m latencies in different patient groups. In parentheses, the number of
abnormal responses of all the responses evoked by left or right median nerve stimulation are given.
Age JNCL-I JNCL-II NES vLINCLFin
 < 11.0 years 0% (0/5) 0% (0/4)  - 100% (2/2)
> 11.0 years 36% (8/22) 78% (7/9) 0% (0/8) 100% (5/5)
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6.1.2. Responses from the Ipsilateral SI (IV)
Healthy Controls
Activity from the ipsilateral SI was found in 6 of the 10 control subjects in Study IV: in one
subject in both hemispheres, in 2 in the right hemisphere, and in 3 in the left hemisphere. The
latencies varied between 44 and 165 ms and the ECD strengths between 6 and 74 nAm.
Patients
Activity from the ipsilateral SI was examined only in patients with vLINCLFin. Two of the three
patients, in whom the LMN was stimulated showed activity at ipsilateral SI; however, only in one
patient this could be modelled with an ECD (peak was at 77 ms with a strength of 33 nAm).
RMN stimulation did not reveal any ipsilateral SI activity in the patients.
6.1.3. Responses from SII (III and IV)
Healthy Controls
Most of the 18 healthy control subjects studied had activity at the frontoparietal opercular regions;
however the strength of the activity was in some cases weak and dipole modelling could not be
performed. Thus, the SIIc deflection was modelled in 13 and 15 of the controls after LMN and
RMN stimulation, respectively. The SIIi deflection was amenable to modelling in 10 and 13 of
the subjects after LMN and RMN stimulation, respectively. The locations of the acceptable ECDs
of these responses were in the vicinity of the lateral sulcus near the SII area.
The dipole moments varied between 6–90 and 8–42 nAm for SIIc and SIIi responses, but only the
dipole moment of SIIi to RMN stimulation was correlated with age (p = 0.006 and rS= 0.71,
Figure 9). The only significant differences between the strengths of the responses to LMN or
RMN stimulation was that the SIIi was stronger to LMN stimulation (p = 0.04). The SIIc
deflections for RMN were significantly stronger than the SIIi deflections (p = 0.01), but to LMN
stimulation there was no significant differences between the SIIc and SIIi strengths. Gender did
not affect the response strengths.
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Figure 9. The strengths of SIIc and SIIi ECDs in healthy control subjects as a function of age.
The range of the SIIc peak latencies in all the controls was 91–197 and 79–185 ms to LMN and
RMN stimulation, respectively. The range of peak latencies of the SIIi responses was 79–199 and
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111–200 ms to LMN and RMN stimulation, respectively. This wide range was due to the fact that
if the first deflection of the bi-phasic responses was not clearly detectable, the SII responses were
modelled from the second deflection. The latencies of SIIc or SIIi responses for either median
nerves did not correlate with age, nor were there significant differences between the deflections to
RMN and LMN stimulation. The SIIc deflections to RMN, but not to LMN stimulation, peaked
significantly earlier than the SIIi deflections (p = 0.03).
Patients
The SII responses were evaluated in vLINCLFin and NES. The SII response was basically a bi-
phasic response. The SII ECDs were generally located in the vicinity of the lateral sulcus (Figure
10). The SII responses seemed to be equally often present in patients with NES than in controls.
All patients with vLINCLFin had SIIc responses, but the SIIi response was missing from 4 out of 7
hemispheres (Table 7).
The SII dipole moments were within the range of the controls’ dipole moments in the patients
with NES (25–32 and 14–55 nAm for SIIc and 10–19 and 8–25 nAm for SIIi to LMN and RMN
stimulation, respectively). In patients with vLINCLFin the dipole moment of the SIIc response was
enlarged in 4 out of the 5 patients, whereas the SIIi response was enlarged in two of the three
patients in whom it was present (Table 7).
Figure 10. A T1-weighted
coronal MRI of 40-year-old
patient with NES. The
circle denotes the location
of P35m and squares the
location of SII ECDs to
LMN stimulation. L = left,
R = right.
L                                                                  R
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Table 7. The latencies and dipole moments of the earliest SII response peaks in patients with vLINCLFin, and the
normal limits established from the values of age-matched controls
SIIc SIIi
Age LMN RMN LMN RMN
[years]
Peak
[ms]
Peak strength
[nAm]
Peak
[ms]
Peak strength
[nAm]
Peak
[ms]
Peak strength
[nAm]
Peak
[ms]
Peak strength
[nAm]
9.1 na na 79 39 na na – –
12.3 97 45 57 118 – – 68 26
16.7 na na 65 169 na na – –
8.8 106 122 na na 77 82 na na
12.5 59 229 105 218 – – 112 123
Normal
limits
91–197
(n = 8)
0–30 79–185
(n = 9)
0–60 79–199
(n = 6)
0–32 111–200
(n = 7)
0–32
na = data not available, – = no SII responses were detected. The latencies below the range of normal values in
controls and the enlarged ECD strengths are in bold typeface.
In patients with NES the SII response latencies fell within the range of latencies of the healthy
controls. The peaks of the main SII responses in the patients with vLINCLFin were generally of
short latency compared with those of the controls: 4 patients had peak latencies below the normal
range determined from the controls’ values (Table 7). When the onset of the SII activity was
judged from the multidipole models (Figure 11), both SIIc and SIIi sources were activated 20–
35 ms after stimulus in all patients. In contrast, only 2 of the controls had SIIc activity before 35
ms; otherwise the SIIc and SIIi onset ranges in the controls were 40–120 and 60–150 ms,
respectively.
Figure 11. The multidipole model of
responses from an 8-year-old
vLINCLFin patient showing the time
courses of the SI, SIIc and SIIi ECD
strengths. The arrows indicate the
occurrence of the stimulus at 0 ms.
The goodness-of-fit value of the
multidipole model is expressed as g
at the bottom. The isofield contour
maps of the individual sources, at the
latencies specified with the asterisks,
are shown on the right. The dashed
lines indicate magnetic flux entering
and solid lines magnetic flux exiting
the head. The contour step is 200 and
50 fT for the SI and SII responses,
respectively. SII activity can be seen
on the traces starting 25–35 ms after
stimulus, however, the main SII peak
starts later.
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*
*
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6.2. MRI (I–IV)
6.2.1. Patients with JNCL (I and II)
Atrophic changes of the cerebellum and cerebrum were observed in patients older than 11 years
in both JNCL–I and JNCL–II groups (Table 8). In addition, one compound heterozygous patient
had slightly dilated lateral ventricles already at the age of 8 years. Analysis of previously taken
T2-weighted images of eleven of the homozygous patients showed abnormally high signal
intensity of the periventricular white matter in three patients, at the ages of 11, 12, and 14 years.
This alteration was seen only in one compound heterozygous patient at the age of 9 years. None
of the compound heterozygous patients had abnormally low signal intensity ratios between the
deep grey matter structures and the white matter, whereas this alteration was seen in one
homozygous patient at the age of 17.
Table 8. MRI findings in 17 patients with JNCL at the time of SEF measurement
Cerebellar atrophy Cerebral atrophy
Age JNCL–I JNCL–II JNCL–I JNCL–II
< 11.0 years 0% (0/3) 0% (0/1) 0% (0/3) 0% (0/1)
> 11.0 years 56% (5/9) 25% (1/4) 89% (8/9) 50% (2/4)
6.2.2. Patients with NES (III)
Cerebellar atrophy with enlarged (> 2 mm) cerebellar fissures was seen in all four patients; the
atrophy was graded slight in two patients and moderate in the other two (Table 9). The size of the
cerebral central CSF spaces was visually judged to be normal in all patients, whereas peripheral
CSF spaces were slightly enlarged in two patients. However, similar grade 2 peripheral CSF
spaces are seen in 10–20% of the control population of the same age (Salonen et al., 1997). The
midsagittal brain area was within normal limits in all patients. The corpus callosum was graded
visually to be normal in the two youngest patients, but the measurements revealed that it was
below normal limits in one of them, as it was in the two oldest patients in whom the corpus
callosum was visually graded to be thin.
Table 9. MRI results in 4 patients with NES
Age Cerebellar Cerebral Mesen- Pons Medulla Corpus callosum (CC) Brain CC/
atrophy atrophy cephalon oblongata genu body splenium area area brain area
[years] [mm] [mm] [mm] [mm] [mm] [mm] [cm2] [cm2] %
26 Slight Normal 14 19 11 10 6 10 5.0 143 3.5
30 Moderate Slight 14 20 11 9 4 8 5.8 148 3.9
40 Slight Normal 16 22 11 8 5 8 4.6 139 3.3
43 Moderate Slight 14 20 10 6 3 7 4.2 125 3.4
Normal
limits
16–19 21–26 11–15 9–15 5–8 8–14 5.1–8.7 125–202 3.3–5.2
Bold typeface = values outside normal limits (calculated from the normal controls’ mean ± 2 SD values)
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The CC/brain area ratios were within normal limits in all patients indicating that the corpus
callosum is of relatively normal size when the size of the brain is taken into account. The
measured diameters of the brain stem had values below normal limits in three patients.
The general grey to white matter differentiation was normal, and no focal signal intensity
abnormalities were found in patients or in the post-mortem brain.
6.2.3. Patients with vLINCLFin (IV)
All the four patients that had MRI at the time of the SEF recording showed both cerebellar and
cerebral atrophy. Only in the youngest patient, aged 8.8 years, was the cerebral atrophy graded
slight, the other patients had moderate to severe atrophy (Figure 12). Cerebellar atrophy was
graded moderate to severe in all the four patients. A notable feature was also the thinning of the
corpus callosum in all the patients. Abnormal signal intensity changes of the deep grey matter
structures on T2-weighted images (abnormally low signal intensity of the thalamus, abnormally
high signal intensity of the posterior limb of capsula interna) and abnormally high signal intensity
of the periventricular white matter were previously observed in all the patients (Holmberg et al.,
2000).
Figure 12. A sagittal T1-weighted MPRAGE image of a 8.8-year-old patient with vLINCLFin on the left and of a
16.7-year-old patient on the right. In the younger patient, the cerebrum is only slightly atrophic, whereas the corpus
callosum is thin and cerebellum moderately atrophic. In the older patient, the cerebrum and cerebellum are extremely
atrophic and corpus callosum is extremely thin. Note also the thickening of the skull in the older patient.
6.3. EFFECT OF THE GENOTYPE ON THE PHENOTYPE (I, II, IV)
6.3.1. Patients with JNCL (I and II)
Clinically, the patients with JNCL were classified to have three different types of disease
progression (Table 10), the delayed classic course of which was seen most commonly, in
altogether 15 of the 24 patients. The classic course was seen in 7 patients, all of whom were
homozygous for the major 1.02-kb deletion.
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Table 10. Genotype, clinical phenotype, SEF and MRI findings in 24 patients with JNCL
SEFs (LMN/RMN) MRI
Mutations Location Phenotype AED N20m
latency
N20m P35m Cerebellar
atrophy
Cerebral
atrophy
[nAm] [nAm]
1 1.02-kb del/
   1.02 kb del
Intron 6–8/
   intron 6–8
Classic (14) – 19/19 (9) 17/14 40/36 – (9) –
2* “ “ “ (15) – 20/20 (10) 15/18 41/33 – (10) –
3 “ “ “ (17) LTG 20/20 (11) 28/19 102/98 – (11) –
4* “ “ “ (18) LTG, VPA 23/23 (14) 23/19 59/56 – (14) +
5* “ “ “ (19) LTG 20/20 (15) 26/43 64/72 – (14) ++
6 “ “ “ (21) VPA, CZP 19/20 (17) 15/20 59/61 + (17) +
7 “ “ “ (22) VPA 21/21 (18) 40/57 91/100 + (18) ++
8 “ “ Delayed
   classic (12)
– na/18 (6) na/13 na/24 – (6) –
9* “ “ “ (19) – 20/20 (15) 21/22 45/41 – (15) +
10 “ “ “ (22) VPA 20/20 (16) 12/24 47/38 + (16) +
11 “ “ “ (23) VPA 21/21 (16) 25/25 63/73 +/– (16) +
12* “ “ “ (21) VPA 21/21 (17) 40/33 97/75 + (16) ++
13* “ “ “ (24) VPA 25/25 (18) 29/38 36/33 – (18) +
14 “ “ “ (26) VPA 22/23 (20) 57/49 54/67 + (21) +
15 1.02-kb del/
   2.8-kb del1
Intron 6–8/
   intron 9–13
Delayed
   classic (7)
– na na
16 “ “ “ (7) – na/17 (7) na/10 na/57 – (6) –
17 “ “ “ (8) – na/19 (8) na/12 na/56 – (8) –
18 “ “ “ (12) LTG 19/19 (10) 13/9 30/24 – (8) +
19 “ “ “ (15) LTG na/22 (14) na/39 na/95 – (14) –
20 “ “ “ (15) LTG 21/22 (15) 39/24 48/46 – (15) +
21 1.02-kb del/
   2.8-kb del
Intron 6–8/
   intron 9–13
“ (20) VPA, CZP 23/23 (19) 60/51 108/101 + (18) –
22 1.02-kb del/
   splice site
Intron 6–8/
   intron 7
“ (15)2 VPA na na na – (9) –
23 1.02-kb del/
   missense
Intron 6–8/
   exon 11
Protracted (32) LTG 25/25 (30) 22/34 51/35 ++ (30) +
24 1.02-kb del/
   missense
Intron 6–8/
   exon 13
Protracted (16) LTG 20/20 (13) 8/21 26/56 – (13) –
Patients 1–14 form the JNCL–I group (* novel patients) and patients 15–24 form the JNCL–II group. 1this novel
deletion is reported in Study II of this Thesis, 2the mental decline in this patient resembled that seen in classic JNCL.
In parenthesis are the ages (in years) the examinations were done. Bold typeface = delayed N20m response or
abnormally strong response. – = not present or normal, + = slight atrophy, ++ = moderate or severe atrophy. AED =
antiepileptic medication, CZP = clonazepam, LTG = lamotrigine, VPA = valproate, na = data not available
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Among the patients with the delayed classic course, cerebral and cerebellar atrophy on MRI
seemed to be present equally often in the patients homozygous for the 1.02-kb deletion than in the
compound heterozygotes. In addition, the SEFs were similarly altered in compound heterozygotes
as in homozygous patients: most patients over 11 years had abnormally strong N20m responses,
and in eight patients the P35m responses were also enlarged. In fact, the age of the patient, and
thus the duration of the disease, seemed to be a better predictor for an enlarged response than the
genotype.
A clearly more slowly progressing disease, defined as protracted, was seen in the two patients
with missense mutations in exons 11 (Gly295Lys) and 13 (Arg334His). The 30-year-patient had
only slightly enlarged cerebral sulci in MRI, normal corpus callosum and thalamic signal
intensity, but his cerebellar atrophy was moderate. He had only one enlarged SEF deflection (the
N20m to RMN stimulation). The other patient had normal SEFs and MRI at the age of 13.
6.3.2. Patients with vLINCLFin (IV)
The three different genotypes (Table 11) in patients with vLINCLFin did not cause phenotypic
differences in the SEF response waveforms, locations or latencies. However, although all patients
had enhanced responses, the lowest SI and SII response strengths were seen in patients
homozygous for the 2-bp deletion (the Fin major) mutation, which is predicted to result in a less
truncated polypeptide than the other two mutations in the patients of this study.
Table 11. MRI and SEF findings in 5 patients with vLINCLFin
MRI SEFs (LMN/RMN)
Mutations Predicted
effect1
Age
[years]
Cerebellar
atrophy
Cerebral
atrophy
Corpus
callosum
N20m
[nAm]
P35m
[nAm]
SIIc
[nAm]
SIIi
[nAm]
1 2-bp del/
2-bp del
Tyr392
Stop
  9.1 na na na na/100 na/262 na/39 na/–
2 “ “ 12.3 Moderate Moderate Thin 94/70 244/356 45/118 –/26
3 “ “ 16.7 Severe Severe Very
thin
na/240 na/499 na/169 na/–
4 2-bp del/
1-bp ins
Glu253
Stop
  8.8 Moderate Slight Thin 119/na 414/na 122/na 82/na
5 Nonsense/
nonsense
Trp75
Stop
12.5 Moderate Moderate Thin
splenium
171/287 406/611 229/218 –/123
1 of the second mutation, na = not available, – = not detected, dipole moments over the upper normal
limits are in bold typeface
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7. DISCUSSION
In this Thesis, we were able to demonstrate previously unknown alterations in the somatosensory
evoked responses in NCL diseases by using MEG. In Studies I and II, an enlargement of the early
SI SEFs with the progression of JNCL was demonstrated in both homozygous and compound
heterozygous patients. In Study III, the newest member of the NCL disease group, NES, was
found to be associated with extremely mild cerebral MRI and SEF findings. Study IV
demonstrated that the increased excitability of the somatosensory system in vLINCLFin extends
also to SII areas. Furthermore, when combined, the SEFs from the control subjects from Studies
I–IV form the largest published material of SEFs in healthy children and adolescents.
7.1. METHODOLOGICAL ISSUES
7.1.1. Patient and Control Groups
Because of the rare nature of NCL diseases, the number of patients was known from the
beginning of the studies to be small. Patients were recruited between 1995 and 1998, and some
patients with JNCL are included in this Thesis that were not included in the original publications.
Thus, we were able to perform statistical evaluation between the JNCL groups as well as between
patients with JNCL and controls. Unfortunately, the small number of patients with NES and
vLINCLFin did not allow statistical group comparisons to be carried out.
When the patients with JNCL were measured for Study I the underlying mutations were not
known. As the mutations were characterized it became apparent that several different mutations
were present in the Finnish JNCL patient group, and that some genotype-phenotype correlation
could exist (Järvelä et al., 1997). Thus, when a novel mutation was found in six patients from
three Finnish families, Study II was performed in order to evaluate the genotype-phenotype
relation in the compound heterozygous patients with JNCL. Because the imaging and
neurophysiological data was retrospectively collected, the patients had undergone the different
investigations at different ages, which made the evaluation of the data more difficult.
At the beginning of this study, no normative data of SEFs in children was available in the
literature. However, based on SEP studies, age-related changes in SEFs were expected in the
different age ranges of NCL patients (Allison et al., 1983, 1984; Taylor and Fagan, 1988; Araki et
al., 1999). Therefore, an age-matched control group was recorded for each study for comparisons
of the SEFs in the specific age groups. Adult controls were measured for Study III, because
although there was more knowledge of the SEFs in the age group 26–43 years, our recording
parameters differed slightly from those reported, and thus a control group was needed. Within the
control groups in Studies I–IV the ECD parameters other than latencies were not found to
correlate with age, and thus the same normal limits were used for the whole age range in each
study. For this Thesis, all the controls were presented together, thus forming a group of 27
individuals, with an age range of 6.5–44 years. Since the main purpose of this Thesis was to
elucidate the alterations caused by NCL diseases, the findings in the control group were not
analyzed in detail. However, since novel information about the development of SEFs with age
can obviously be deduced from the control group, a thorough evaluation of the SEFs in these
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normal subjects will be done in the future. In fact, by measuring some new controls, proper
reference limits of SEFs can be set for different age groups and the effect of maturation of SEFs,
unknown at present, can be assessed.
7.1.2. SEFs
Whole-head MEG was chosen for evaluating the somatosensory system in NCL diseases for
several reasons. Previous reports on patients with JNCL have been inconsistent regarding the SEP
amplitudes. They have been described as normal (Cracco et al., 1980; Harden and Pampiglione,
1982), decreased (Goebel, 1995) or enhanced (Schmitt et al., 1994). However, the SEP
amplitudes may be affected by the changes of conductivity between the brain source and
recording electrodes caused by the disease, which include thickening of the skull, increase of CSF
volume, decrease of brain tissue and gliosis (Zeman et al., 1970; Autti et al., 1997a). Since these
changes do not affect the magnetic fields measured with MEG, it should give a more accurate
estimate of the strengths of the underlying neuronal activation (Hämäläinen et al., 1993). In
vLINCLFin, the SEPs are known to be giant (Santavuori et al., 1982, 1991). However, no source
modelling of the responses has been performed, and it is not known whether the giant responses
originate only from the SI. Thus, whole-head MEG, which offers a possibility to study the
activation of the whole brain simultaneously, and to localize accurately the activity within the
brain, seemed well suited for the study of the somatosensory system in NCL.
The young age of some of the subjects brought up some specific difficulties in the MEG
recording session. The helmet of the MEG measurement device accommodates most adult size
heads, and thus additional cushions were needed to make the child subject’s head fit snugly inside
the helmet. However, it is not impossible that the subject moved after the determination of the
indicator coils used in aligning the MEG and MRI coordinate systems or even during the
measurement, and thus the localization accuracy of the ECDs in these subjects was not expected
to be as good as for co-operating adults. However, the repeatability of the recordings, which was
evaluated by repeating most of the measurement runs, was good. Accordingly, the sources of
ECDs, determined from the individual MRIs, were located in the vicinity of the SI and SII areas.
In both the control subjects and the patients the modelling and localization of the SII sources was
more difficult than those of the SI. This could be due to, e.g., the use of spherical model, since the
sphere was defined to approximate primarily the parietal SI areas. In addition, different opercular
areas may be active simultaneously (Korvenoja et al., 1999), which can hamper the SII dipole
modelling. However, we considered that the most important aspect of the localization of the
ECDs was that we could demonstrate that the abnormally enlarged response components in
patients originated within or in the proximity of the SI and SII areas.
Although our aim was to stimulate both median nerves of each subject, in six of the patients only
one side was stimulated because of restlessness or poor condition of the patient. However, in
general the recordings went surprisingly well. Most of the patients sat still and listened to the
story that was read to them or watched a video film. However, at the time the recordings were
done, sitting was the only position possible for the subjects. Furthermore, the patients’ custom-
made wheelchairs could not be taken inside the measurement room because of the magnetic
artefacts, which made the most severely affected patients feel uncomfortable. Nowadays,
significant improvements have been made, as the MEG recordings can now be done in the supine
position.
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7.1.3. MRI
The MRI findings in patients with JNCL and vLINCLFin have been recently described and the
present study did not aim to repeat these descriptions. However, since 25 of the patients
underwent MRI, the atrophic changes were evaluated as described earlier (Autti et al., 1996) in
order to relate the SEF findings to the macroscopical atrophic changes. The MRI of patients with
NES were described more thoroughly, because the findings had not been described in the context
of NCL diseases. However, since the patients with NES were adults, the same normative values
that had been used for other NCL patients were not applicable. Thus, with NES, the measured
values of some of the brain structures were compared to those 8 controls that underwent SEF
studies as controls for NES patients. The normal values established from these controls were
found correlate well with the normative data published earlier (Laissy et al., 1993; Raininko et
al., 1994). The sizes of the cerebrospinal fluid spaces were compared to those of a previously
described large normal material of Finnish adults (Salonen et al., 1997).
7.2. SEFS IN HEALTHY CONTROLS
When all controls from Studies I–IV are compiled, they form a group of 27 healthy subjects, (13
males, 14 females), with an age range of 6–44 years (mean 19 years). Seventeen of the subjects
were younger than 19 years, which makes this study the first to publish SEFs of a relative large
number of young subjects. The SEF waveforms and ECD locations in the adult controls
corresponded well to other published findings in normal subjects (e.g., Wikström et al., 1997).
However, some age-related alterations in the SEF strengths and latencies were seen. The controls
over 25 years of age had stronger N20m responses than younger subjects, in line with the
previous analysis of age-related changes in SEFs of adults (Huttunen et al., 1999). In addition,
there was a tendency for the P35m to be stronger in older subjects this correlation being
significant, however, only to right median nerve stimulation. In the study of Huttunen et al.
(1999), there were no age-related changes of the P35m strength, although in SEP studies older
subjects may have stronger late SI responses (Kakigi and Shibasaki, 1991). The dipole moments
of the deflections studied did not differ significantly between males and females, corroborating
the previous SEF study (Huttunen et al., 1999).
The SII responses could be modelled in 72–83% (SIIc) and 56–72% (SIIi) of the subjects. This
partial lack of SII responses, and especially the SIIi responses, is similar to those reported in one
previous study (Wikström et al., 1996). However, in some other studies the SII responses have
been present in all subjects (e.g., Forss et al., 1994a; Mauguière et al., 1997b; Simões and Hari,
1999; Lin et al., 2000). This discrepancy could be due to the relatively short ISI we used, since
the SII responses become stronger with increasing ISI up to at least 3 s (Hari et al., 1993; Forss et
al., 1994a; Wikström et al., 1996). In addition, although the SII responses seemed to be present as
frequently in our older control subjects as in the younger, some age related differences in the
presence of SII responses cannot be ruled out. In SEP studies, the evoked responses in children of
different ages have been shown to be affected differently by the changes of ISI (Araki et al.,
1999). Nevertheless, since the SII responses were not detected in a relatively large number of our
control subjects, a similar lack of the SII responses in patients was considered normal.
The interindividual variability in the strengths of the SII dipole moments was large: they were
between 6–67 nAm (and in one control even 90 nAm). However, the age of the subject was not a
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significant factor in determining the strength of SII responses since only SIIi to RMN stimulation
correlated with age. The SIIc deflections were statistically stronger than the SIIi deflections as
reported previously (Hari et al., 1983, 1984; Mima et al., 1998a), although statistically
significantly to right median nerve stimulation only. The only hemispheric difference found was
that the left hemisphere SIIi was weaker than the right hemisphere SIIi. Thus, our results are in
line with some previous studies (Wikström et al., 1997; Wegner et al., 2000), but we can not
corroborate other studies showing stronger, earlier peaking and more posteriorly located left
hemisphere SII responses (Forss et al., 1994a; Simões and Hari, 1999; Lin et al., 2000).
The latency of N20m correlated with age and height, as expected from previous SEP studies
(Allison et al., 1983, 1984; Zhu et al., 1987; Taylor and Fagan, 1988). The N20m peaked
significantly later in males than in females, this difference most likely reflecting the taller stature
of the males. The range of SII latencies in the control subjects was wide, peaking at the earliest
around 80 ms, in agreement with previous reports (Hari et al., 1984; Mauguière et al., 1997b;
Wegner et al., 2000), but at the latest not until 200 ms. This wide latency range was due to the
fact that the responses were modelled either from the first or second deflection of the bi-phasic
response, thus making the normal limits for the latencies very wide. However, the previously
observed tendency of the SIIc deflections to peak earlier than the SIIi deflections was also
demonstrated in the present study (Forss et al., 1994a; Simões and Hari, 1999; Wegner et al.,
2000), although it became statistically significant only to right median nerve stimulation.
7.3. SEFS IN PATIENTS WITH JNCL, NES AND VLINCLFin
The most remarkable finding in patients with JNCL and vLINCLFin was the enlargement of the SI
responses compared with healthy controls and patients with NES. Similar enlarged or giant
somatosensory evoked responses are usually reported in patients with cortical myoclonus, most
often diagnosed with PME (e.g., Rothwell et al., 1984; Obeso et al., 1985; Shibasaki et al., 1985;
Berkovic et al., 1991; Karhu et al., 1994; Mima et al., 1998b; Forss et al., 2001). However,
enlarged SEPs/SEFs have also been reported in patients without myoclonus, e.g., in benign
rolandic epilepsy (Kubota et al., 2000), and in patients with heterogeneous diagnoses
(Micheloyannis et al., 1989; Schmitt et al., 1994). Out of these groups our patients have much in
common with PME (Berkovic et al., 1986). In patients with vLINCLFin, frequent myoclonus is
seen from the age of 8–10 years, whereas the myoclonus in patients with JNCL is a later feature
of the disease, and may be subtle or even undetected. Although the patients with JNCL in this
study did not have clinically evident myoclonus, the increased excitability of SI may precede
clinical myoclonus. This assumption is supported by the findings of giant SEPs in patients with
other NCL forms that classically have myoclonus, including other LINCL forms and some
patients with the adult (Kufs) form of NCL (Harden and Pampiglione, 1982; Vercruyssen et al.,
1982). On the other hand, SEFs were normal in patients with NES that is not associated with
myoclonus.
Compared with the previously published enlarged SEPs/SEFs in other CNS disorders, the most
striking feature in JNCL and vLINCLFin was the enlargement of the earliest cortical deflection,
N20m. In the previous reports of patients with enlarged or giant responses, the 20-ms deflections
(N20/N20m) have been normal or only slightly enhanced (Rothwell et al., 1984; Obeso et al.,
1985; Shibasaki et al., 1985; Uesaka et al., 1993; Karhu et al., 1994; Mima et al., 1998b; Forss et
al., 2001 ). The 30–40-ms deflections (P30/P35m), which were usually most increased, were also
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enlarged in the patients with vLINCLFin, but only in one third of the patients with JNCL. These
findings suggest that the enlargement of N20m reflects pathophysiological events specific for
NCLs. Since MEG measures postsynaptic currents at the population level, the enlargement of the
N20m (and possibly also that of P35m) could result from increased synchronous thalamic input to
area 3b, which could originate at several levels of the afferent pathway. For example, the
responses could be hypersynchronized at the thalamic level: after destruction of a part of thalamic
neurons, the remaining neurons could sprout to innervate a greater than normal amount of cortical
neurons. In vLINCLFin, thalamic abnormality is constantly seen on MRIs from 6 years onward,
and in several patients with JNCL from 10 years onward (Autti et al., 1992, 1996; Holmberg
et al., 2000). In histopathological analysis, the thalamus shows severe loss of neurons in
vLINCLFin, whereas especially the medial parts of the thalamus are affected in patients with
JNCL (Autti et al., 1997a; Tyynelä et al., 1997).
Two recent studies suggest that increased excitability of the sensorimotor cortex can be a distant
effect of cerebellar pathology (Kolodziejak et al., 2000; Tijssen et al., 2000). This proposition is
also intriguing with respect to some NCL diseases, since late infantile NCL forms have prominent
cerebellar atrophy (Dunn, 1987; Autti et al., 1992; Wisniewski et al., 1993; Petersen et al., 1996;
Holmberg et al., 2000) and are associated with especially large somatosensory cortical responses
(the present study; Harden and Pampiglione, 1982). In juvenile NCL, both the cerebellar atrophy
and enhancement of the SEFs manifest themselves later and are not so severe as in late infantile
NCL (the present study; Autti et al., 1996; Järvelä et al., 1997). In addition, the lack of NCL
specific storage material in the cerebellum of patients with NES (Haltia et al., 1999; Herva et al.,
2000) and the normal SEFs found in this study would support this hypothesis.
At the cortical level, the enlarged response strengths could also result from defective presynaptic
inhibition or from altered membrane or cable properties of the pyramidal cells. The possible
effect of the altered neuronal structure cannot be ruled out in NCL, since in addition to the
advanced loss of neurons in the cerebral cortex in vLINCLFin and JNCL, the remaining cortical
neurons have prominent storage (Zeman et al., 1970; Tyynelä et al., 1997). In studies of NCL
animal models, defective GABAergic (γ–aminobutyric acid) inhibition has been suggested to
underlie neuronal death (March et al., 1995; Walkley et al., 1995). Furthermore, a recent study in
mnd mice, a naturally occurring NCL animal model, has shown that subpopulations of
interneurons are affected differently (Cooper et al., 1999). According to a model of SEF
generators proposed by Wikström et al. (1996), the missing P60m deflection in patients with
vLINCLFin may reflect decreased inhibition due to a missing subpopulation of interneurons. This
lack of inhibition could leave secondary EPSPs unmasked, and thus allow the N45m deflection to
emerge.
An interesting finding in vLINCLFin was that the responses from SII were also enlarged in four
out of five patients. However, SIIi responses were not detected in some patients despite enhanced
SIIc responses. This relative lack of SIIi responses could be due to diminished transcallosal
connections, since all patients had a significantly thinned corpus callosum. Deficient transcallosal
signalling could also explain the fact that responses from the ipsilateral SI, which has been
detected in several other patients with PME (Mima et al., 1998b; Forss et al., 2001), were seen
only in one of our patients.
In addition to the enlargement of the deflections, neuronal dysfunction was demonstrated in the
N20m response latencies. All patients with vLINCLFin had moderately prolonged N20m latency.
In patients with JNCL, the latencies of N20m were slightly prolonged, and in patients with NES
the latencies were within normal limits. Similar latency prolongations have been reported in some
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patients with PME (Mervaala et al., 1984; Karhu et al., 1994), but not in all of them (Uesaka et
al., 1993; Mima et al., 1998b; Forss et al., 2001). In other NCL patients, the latencies have been
reported to be normal or slightly delayed (Westmoreland et al., 1979; Vercruyssen et al., 1982).
Although peripheral neuropathy is not a usual finding in these NCL forms, the latency
prolongation in the patients we studied, may partially reflect slower conduction in the peripheral
nerves that show mild changes in axons and myelin (Blatt Lyon, 1975; Goebel et al., 1976b; Elze
et al., 1978). Because MEG only measures the cortical responses, the level of conduction delay
cannot be determined from MEG results only. Simultaneous recording of SEPs or studies of
peripheral nerve conduction with MEG could in the future help to determine whether the latency
prolongation is due to peripheral or central nervous system damage. However, it seems that in our
patients a significant part of the latency prolongation is due to slower conduction in the CNS,
since the white matter is pathologically altered in MRI. This alteration, seen as increased signal
intensity on the T2-weighted MRIs, is seen especially in the periventricular areas and the
posterior limb of capsula interna in vLINCLFin patients (Holmberg et al., 2000). Similar findings
of white matter rims around the lateral ventricles are also seen in patients with JNCL (Autti et al.,
1996), especially in patients homozygous for the major 1.02-kb deletion (Järvelä et al., 1997). At
autopsy, the loss of CNS myelin, especially in the periventricular white matter, is prominent in
vLINCLFin and JNCL (Autti et al., 1997a; Tyynelä et al., 1997), and is believed to reflect
demyelination secondary to neuronal death (Haltia et al., 1973). In NES, the normal N20m
latencies with no white matter alterations in the MRI, are in line with the finding that the white
matter seems to be intact at autopsy (Herva et al., 2000).
The time course of the SII activity in patients with vLINCLFin was different from that of the
control subjects. The main SII peaks were generally earlier in patients than in controls, and in
addition, the activity onset, determined from the multidipole models, was 20 to 35 ms after the
stimulus in patients, often only shortly after the SI activation. This SII activation at short latency
most likely reflects the fact that the enhanced activation strength exceeds the detection threshold
generally earlier than in controls. Previously similar short-latency SII activation has been
suggested by studies using special analysis methods in healthy subjects (Karhu and Tesche, 1999;
Korvenoja et al., 1999).
The medication of the patients was not changed because of the measurements, and it is thus
possible it had an effect on the SEFs in some of the patients. However, it seems that most of the
antiepileptic drugs the patients used do not affect somatosensory evoked responses significantly
(Borah and Matheshwari, 1985; Mervaala et al., 1987; Mauguière et al., 1997a; Klamt and
Posner, 1999). However, at least some benzodiazepines seem to prolong N20 latency and lower
its amplitude (Sloan et al., 1990; Lauer et al., 1994), although not all studies have observed this
amplitude change (Koht et al., 1988). In our study, clonazepam was used by one homozygous and
one compound heterozygous patient with JNCL, two vLINCLFin and all NES patients. The N20m
latencies in patients with NES were within normal limits, but the effect of clonazepam on the
SEF strengths can not be excluded since the strengths were mainly within normal limits.
However, at least in the patients with JNCL and vLINCLFin, the use of clonazepam was
associated with similarly enlarged SEFs as with the other patients. In fact, the two vLINCLFin
patients on clonazepam had enlarged SEFs with delayed N20m latency as did the patients without
clonazepam. It is possible that some of the latency prolongation in them may have resulted from
the medication. The compound heterozygous patient with JNCL had delayed N20m latency and
increased strength of N20m and P35m, whereas the homozygous patient with JNCL had a normal
N20m latency and strength. Thus, although the medication used, especially clonazepam, may
have had some effects on the evoked responses, it is likely that the results are not significantly
influenced by the patients’ medication.
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7.4. MRI FINDINGS
The MRIs of patients with JNCL and vLINCLFin showed features typical for these diseases, as
reported earlier (Autti et al., 1992, 1996; Holmberg et al., 2000). This was the first study to report
the MRI findings of patients with NES in the context of NCL diseases. The major differences in
MRI findings between NES and other NCL forms were the relatively well preserved cerebrum
and normal grey to white matter differentiation seen in NES. In two patients, aged 26 and 40
years, there was no atrophy, and this was neither reported in the two previously described patients
who were under 16 (Hirvasniemi and Karumo, 1994). Furthermore, the slight enlargement of
cerebrospinal fluid spaces seen in the two male patients, at the ages of 30 and 43 years, is similar
to that reported in 10–20% of healthy controls of the same age groups (Salonen et al., 1997) and
can thus not be considered abnormal or even to be necessarily related to the disease. On the
contrary, all patients with vLINCLFin have cerebral atrophy at least from 9 years onward (Autti et
al., 1992; Holmberg et al., 2000), and in JNCL cerebral atrophy is seen in most patients after 15
years of age (Autti et al., 1996; Järvelä et al., 1997). In addition, no signal intensity alterations
were seen in patients with NES, in contrast to JNCL and vLINCLFin, which show impressions of
pathologically dark thalami after 10 and 6 years, respectively (Autti et al., 1992, 1996; Järvelä et
al., 1997; Holmberg et al., 2000). Thus, the normal MRI findings, in addition to the normal SEFs,
support the autopsy findings that the overall degree of intraneuronal storage, neuronal loss, and
secondary astrocytic and microglial reactions are much less pronounced in NES than in other
childhood onset NCL forms (Herva et al., 2000).
However, a slight discrepancy was seen in the cerebellar findings compared with histopathology.
At autopsy, the cerebellum of patients with NES is relatively well preserved, showing only
modest storage in granular cells (Herva et al., 2000). However, in our MRIs and in previous CT
studies, all patients over 10 years had cerebellar atrophy (Hirvasniemi and Karumo, 1994).
Similar early and prominent cerebellar atrophy is typical also in patients with vLINCLFin but not
in patients with JNCL (Autti et al., 1992, 1996; Järvelä et al., 1997; Holmberg et al., 2000).
However, it is possible that in NES the cerebellar atrophy in MRI reflects the antiepileptic
medication (Iivanainen et al., 1977), which in the past has included phenytoin for several years
(Hirvasniemi and Karumo, 1994).
7.5. CORRELATION OF THE GENOTYPE WITH THE PHENOTYPE
After the introduction of genetic diagnosis of NCL diseases, it has become apparent that fairly
similar clinical phenotypes can be caused by mutations in different genes (Das et al., 1998). All
patients here have genetically confirmed diagnoses.
Of the patients with JNCL, 14 were homozygous for the major 1.02-kb deletion that removes
introns 6–8 from the transcript and leads to a truncated protein (The International Batten Disease
Consortium, 1995), and 10 were compound heterozygous for the major mutation and another
CLN3 mutation. A novel mutation, a 2.8-kb genomic deletion that removes exons 10–13, was
described in 6 patients of three families in this study. A distinct, previously described mutation
that leads to deletion of exons 10–13, was seen in one patient (The International Batten Disease
Consortium, 1995). These mutations are predicted to result in truncated proteins, as is the splice
site mutation located in intron 7 that results in a number of aberrantly spliced transcripts. The
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phenotypes of the patients with these different mutations resembled each other and also the one
that was seen in half of the Finnish patients homozygous for the major 1.02-kb deletion (Järvelä
et al., 1997). Thus, clinically the compound heterozygous patients with mutations predicted to
lead to truncated proteins had a similar delayed classic disease course as a half of the
homozygous patients. Also the MRI findings were similar in these two groups, including normal
cerebrum or slight cerebral atrophy in the younger patients and cerebellar atrophy manifestation
in older patients (Autti et al., 1996; Järvelä et al., 1997). However, the cerebral atrophy and brain
tissue signal intensity alterations may manifest themselves later in the compound heterozygous
patients than in the homozygous patients (Järvelä et al., 1997). In contrast to these structural
alterations, in the present study the timing and severity of the SEF abnormality did not differ
between these two genetically different groups, suggesting that the onset of neuronal dysfunction
is not markedly different between them. Similarly, the earlier report showed that the onset of
epilepsy and blindness were highly concordant among these groups (Järvelä et al., 1997).
Furthermore, the environmental factors and modifying genes have been demonstrated to play an
important role in the individual JNCL phenotypes, since the patients homozygous for the 1.02-kb
deletions may have the classic or delayed classic disease course and even the intrafamiliar
variability is large (Järvelä et al., 1997). These observations suggest that although all mutations,
which are predicted to result in truncated proteins, resulted in the delayed classic phenotype in
this study, it may still be that at the cellular level, the mutations lead to similar dysfunction of the
CLN3 protein as the major 1.02-kb deletion.
The proteins affected by the missense mutations may have some residual function, at least enough
to prolong the course of the disease. The missense mutation in exon 11 resulting in a change of
one amino acid (Gly295Lys) seems to cause an extremely mild disease course among the patients
affected with JNCL. Our 30-year-old patient as well as two previously reported siblings of
German origin (Wisniewski et al., 1998) have been blind from the ages of 12–13 years, but
otherwise clinically asymptomatic until at least their forties. The MRI of our patient showed
slight cerebral atrophy, no signal intensity changes and moderate cerebellar atrophy. In SEFs, he
had only a slightly enlarged N20m deflection. The other missense mutation (Arg334His in exon
13) seemed to result in a protracted disease in our patient, although in three previously reported
patients (Munroe et al., 1997) it resulted in classic JNCL phenotype. However, our patient was
only 13 years old, and it is not impossible that he will develop motor and mental symptoms later.
His MRI and SEF findings were normal, which is, however, common in JNCL patients at this
age. However, the phenotypic heterogeneity between these patients with an identical compound
heterozygous mutation in the CLN3 gene may be due to genes that modify the phenotype, but the
effect of early symptomatic medication and rehabilitation should not be overlooked.
In vLINCLFin, no genotype-phenotype correlation has been found between the different
combinations of the known mutations, and it has thus been suggested that each mutation severely
disturbs the normal function of the CLN5 protein (Holmberg et al., 2000). In the present study,
the patients with the mutations predicted to result in the most truncated proteins had the most
enlarged responses, indicating thus a subtle link between genotype and phenotype in vLINCLFin.
However, the small number of patients with different genotypes prevents any definitive
conclusions on the effect of the genotype on the phenotype. Nevertheless, as expected, it was
shown that none of the mutations had left the function of neurons on the somatosensory system
intact. Further studies, using a larger cross-sectional patient group or a longitudinal study of the
same patients, could clarify whether any significant neurophysiological phenotype-genotype
correlations exist.
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8. CONCLUSIONS
The present study reports for the first time median nerve SEFs in a relatively large number of
children and adolescents, indicating that the SEFs in healthy children over 6 years of age are
morphologically similar to those in adults. Novel information about the development of SEFs,
e.g., that both the N20m and P35m may become stronger with age was demonstrated. Further
studies of SEFs in a large number of healthy children and adolescents may help to clarify the
process of maturation of the peripheral and central nervous systems in humans.
The enlarged SEFs in JNCL and vLINCLFin suggest that these diseases lead to a disturbed balance
between inhibition and excitation in the somatosensory network. Furthermore, this increased
excitability of the somatosensory system extended to the opercular SII areas in patients with
vLINCLFin.
The CLN3 gene defects predicted to give rise to truncated proteins resulted in classic or delayed
classic JNCL. Both phenotypes were associated with age-related increase in SEF strengths,
indicating that all underlying mutations similarly affect the functions of the neurons of the
somatosensory system. However, the patients who were compound heterozygous for the 1.02-kb
deletion and two different missense mutations had an atypically protracted disease course,
indicating that these mutations allow CLN3 protein with some preserved function to be encoded.
In NES, the normal SEFs, the well-preserved cerebrum and normal signal intensities of the brain
matter on T2-weighted MRIs suggest that the underlying CLN8 gene defect does not have as
detrimental effects on the neurons of the somatosensory network as the CLN3 and CLN5 gene
defects.
We conclude that studying evoked responses with MEG can bring new information about the
neuronal processing in a degenerative brain disorder like NCL, the progression of which is
associated with alterations in the conductivities of the structures between the active brain area and
the measurement device. The novel information about the altered neuronal processing in NCL
obtained with MEG can, in addition to the findings of the ongoing cell biological and animal
model studies, help to clarify the pathogenesis underlying NCL.
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